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ABSTRACT
Epidemiologic projections indicate that the incidence of Alzheimer’s disease (AD) will
increase dramatically in the coming decades due largely to the demographics of the disease and
our aging population. Associated cognitive and physical decline greatly contributes to disability
in older adults and places considerable burden on the health system, patients, and caregivers.
Bone loss and increased risk of fractures are associated with AD, however little is known about
mechanisms of this association. The body of presented work extends the literature on a
relationship between bone loss and AD. Overall, the presented work provides initial evidence
that accelerated bone loss observed in individuals in the early stages of AD may be partially due
to distortion of central regulatory mechanisms by neurodegeneration. This is the first work to
demonstrate that hypothalamic atrophy is related to bone loss and this relationship may be
mediated by leptin-dependent mechanisms in humans in the early stages of AD.
The work in Chapter 2 assessed bone health in the earliest clinical stages of AD in
comparison to non-demented aging and examined the relationship of bone mineral density
(BMD) with cognitive performance and brain atrophy, both of which are used as surrogate
markers of neurodegeneration. We tested the hypothesis that bone density would be lower in
early AD and associated with brain atrophy and cognitive decline. The results of this cross-
sectional study supported our hypothesis and found that BMD is reduced in men and women in
the earliest clinical stages of AD and associated with brain atrophy and memory decline,
suggesting that central mechanisms may contribute to bone loss in early Alzheimer’s disease.
AD is associated with pathological changes in the hypothalamus, a key regulatory
structure of bone remodeling. The aim of Chapter 3 was to extend previous findings of the
association between BMD and neuroimaging markers of neurodegeneration by looking at global
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and regional, hypothalamus specifically, measures of brain volume in early AD and non-
demented aging. The results demonstrated that in early AD, low BMD was associated with low
volume of gray matter in brain structures predominantly affected by AD early in the disease,
including the hypothalamus, cingulate, and parahippocampal gyri and in the left superior
temporal gyrus and left inferior parietal cortex. No relationship between BMD and regional gray
matter volume was found in non-demented controls. These results suggest that central
mechanisms of bone remodeling may be disrupted by neurodegeneration.
There is very limited guidance in the literature regarding useful and reliable techniques
for studying hypothalamic anatomy using neuroimaging. In Chapter 4, we compared an
automated neuroimaging technique – voxel-based morphometry (VBM) – to a “gold standard”
manual method assessing volumetry of the hypothalamus. The atlas-based VBM volumetry
showed promise as a useful tool for regional volumetry of the hypothalamus and has advantages
over manual tracing as it is currently used. The results of this study provided guidance for
method selection in future work.
In Chapter 5, we further examined the hypothesis that AD may influence bone density in
cortical skeletal sites directly through atrophy of the hypothalamus, the major central regulatory
structure of bone remodeling. We previously reported in cross-section that BMD was lower in
those with early AD and suggested that brain atrophy, specifically of the hypothalamus, was
associated with lower BMD in AD. We now examined if similar results were apparent in a two
year longitudinal study to extend our previous finding of an association between hypothalamic
atrophy and bone density. We also explore predictors of bone loss in AD and healthy aging. Our
results demonstrate that bone loss may be accelerated in AD compared with non-demented
controls. For AD participants, bone loss was associated with hypothalamic atrophy over two
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years. Additionally, bone loss was associated with baseline levels of the vitamin D. For non-
demented participants, bone loss was associated with age, female gender and decline in physical
activity. Different predictors of bone loss may suggest that mechanisms of bone loss may differ
in aging and AD and that neurodegeneration may contribute to bone loss in early AD. These
results extend and strengthen the cross-sectional observations in Chapters 2&3.
The purpose of the work presented in Chapter 6 was to further extend previous
observations by assessing the roles of leptin, growth hormone (GH) and insulin-like growth
factor-1 (IGF-1) , two important regulators of hypothalamic control of bone remodeling, in
mediating relationship between hypothalamic structural changes and bone loss in AD. We used
a hypothetical model with statistical structural equation or path modeling to examine if leptin,
GH, and IGF-I may mediate the relationship between hypothalamic structural changes. The
model demonstrated that hypothalamic atrophy had a direct relationship with bone loss. There
was no apparent association between baseline IGF-1 and leptin with bone loss but we observed
changes in both leptin and IGF-1 over two years that were associated with hypothalamic atrophy.
Leptin increased over two years in AD and increase in leptin was associated with hypothalamic
atrophy. On the other hand, IGF-1 declined over two year and this decrease was associated with
increase in leptin. These results suggest that it is conceivable that central regulatory mechanisms
of bone mass may be disturbed by neurodegeneration leading to bone loss in participants in the
early stages of AD.
In summary, this body of work demonstrates that bone density is reduced in women and
men with early stages of AD and continues to decline over time, exceeding bone loss in non-
demented older adults. While the causes of bone loss in AD remain unclear, the observed
association of hypothalamic atrophy with bone loss suggests neurodegeneration may play a role
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in bone loss observed in AD and highlights a need for further studies. This work also
corroborates other studies on the importance of vitamin D and physical activity for bone health.
The findings of this body of work are important because evidence that bone loss in AD is
associated with the atrophy in regions involved in the central regulation of bone mass may be
relevant to therapeutic strategies to prevent or treat bone loss in AD and neurodegenerative
diseases.
vii
Acknowledgments
I would like to first and foremost thank my parents, who as I have recently learned should
be called "tiger parents." Mom and Dad, thank you for pushing me outside of my comfort zone,
allowing me to grow up strong. Thank you for believing in my strength by teaching me
responsibility. Thank you for providing comfort and support, a place to heal and share joy in
your home, always.
I would like to thank my mentor, Dr. Jeff Burns for his three years of mentoring. I am
very lucky to be able to learn from Dr. Burns and to be a part of his team. Thank you for
providing a care-free and open-to ideas environment with just right proportions of independence
and guidance.
I would also like to thank my committee members Dr. Lisa Stehno-Bittel, Dr. Bill
Brooks, Dr. David Johnson, Dr. Patty Kluding, Dr. Barbara Lukert and Dr. John Stanford for
their dedication, time and expertise. I would especially like to thank Dr. Brooks for the
opportunity to disagree and argue and Dr. Lisa Stehno-Bittel for serving as my co-mentor.
I must also thank Dr. Irina Smirnova who suggested the Physical Therapy and
Rehabilitation Science Department for my consideration and guided and supported me
throughout my years in the program.
I would also thank the Physical Therapy and Rehabilitation Science Department, the
faculty and students. It has been an incredibly enjoyable and wonderful learning experience.
I must thank everyone in the Alzheimer’s and Memory Program for their support. I must
especially thank Dr. Eric Vidoni for patiently and most elegantly handling every “Eric, I have a
question…” situation.
viii
This research would not be possible without dedication and support of all the study
participants and support from the National Institutes of Health, University of Kansas Endowment
Association and the University of Kansas. I especially would like to thank Dr. Nudo and internal
advisory committee of the T32 Training Program in Neurological Rehabilitation for supporting
my education and research.
Finally, my husband, Anatoly, and my daughter, Veronica, thank you! There are no
words in both languages we speak to express how much I love you and treasure your company
and support.
ix
Table of Contents
Abstract......................................................................................................................................... iii
Acknowledgements ..................................................................................................................... vii
Table of Contents ......................................................................................................................... ix
List of Tables and Figures .......................................................................................................... xii
Chapter 1 Introduction ................................................................................................................ 1
1.1 Alzheimer's Disease.................................................................................................................. 2
1.2 Alzheimer's Disease and Bone Loss ......................................................................................... 3
1.3 Bone Metabolism and Regulation of Bone Remodeling .......................................................... 4
1.3.1 Vitamin D .............................................................................................................................. 5
1.3.2 Central Regulation of Bone Remodeling............................................................................... 6
1.4 The Hypothalamus.................................................................................................................. 10
1.5 The Hypothalamus: Changes in AD ....................................................................................... 11
1.6 Neuroimaging ......................................................................................................................... 12
1.7 Potential Mechanisms of Relationship Between Bone Mass and AD .................................... 13
1.8 Significance of Present Work ................................................................................................. 13
1.9 Specific Aims and Statement of Hypotheses .......................................................................... 14
Chapter 2 Preface ....................................................................................................................... 18
Bone Density and Brian Atrophy in Early Alzheimer's Disease
2.1 Abstract ................................................................................................................................... 20
2.2 Introduction............................................................................................................................. 21
2.3 Materials and Methods........................................................................................................... 22
2.4 Results..................................................................................................................................... 27
x
2.5 Discussions ............................................................................................................................. 30
2.6 Tables and Figures .................................................................................................................. 34
Chapter 3 Preface ....................................................................................................................... 38
Reduced Limbic and Hypothalamic Volumes Correlate with Bone Density in Early Alzheimer's
Disease
3.1 Abstract ................................................................................................................................... 40
3.2 Introduction............................................................................................................................. 41
3.3 Materials and Methods........................................................................................................... 43
3.4 Results..................................................................................................................................... 47
3.5 Discussions ............................................................................................................................. 49
3.6 Tables and Figures .................................................................................................................. 54
Chapter 4 Preface ....................................................................................................................... 60
Cross-Sectional Estimation of the Hypothalamic Volume by Atlas-Based VBM Compared to
Manual Tracing in Application to Alzheimer's Disease
4.1 Abstract ................................................................................................................................... 62
4.2 Introduction............................................................................................................................. 63
4.3 Methods .................................................................................................................................. 66
4.4 Results..................................................................................................................................... 72
4.5 Discussions ............................................................................................................................. 74
4.6 Tables and Figures .................................................................................................................. 78
Chapter 5 Preface ....................................................................................................................... 83
Different Predictors Suggest Different Mechanisms of Bone Loss in AD and Aging
5.1 Abstract ................................................................................................................................... 85
xi
5.2 Introduction............................................................................................................................. 86
5.3 Methods .................................................................................................................................. 87
5.4 Results..................................................................................................................................... 92
5.5 Discussions ............................................................................................................................. 95
5.6 Tables and Figures .................................................................................................................. 98
Chapter 6 Preface ..................................................................................................................... 105
Role of Central Hypothalamic Mechanisms in Bone Loss in Alzheimer's Disease: Testing a Path
Model
6.1 Abstract ................................................................................................................................. 107
6.2 Introduction........................................................................................................................... 108
6.3 Data Collection and Methods .............................................................................................. 110
6.4 Results................................................................................................................................... 115
6.5 Discussions ........................................................................................................................... 119
6.6 Tables and Figures ................................................................................................................ 123
Chapter 7 Discussions and Conclusions.................................................................................. 127
7.1 Summary of Findings............................................................................................................ 128
7.2 Overview of Possible Mechanisms of Bone Loss in AD...................................................... 131
7.3 Summary of Finding in Relation to Theories of Brain-Bone Connection ............................ 132
7.4 Clinical Implications............................................................................................................. 135
7.5 Limitations ............................................................................................................................ 135
7.6 Future Directions .................................................................................................................. 138
7.7 Summary of Conclusions...................................................................................................... 142
References .................................................................................................................................. 143
xii
List of Tables and Figures
Chapter 2
Table 2. 1 Sample characteristics.................................................................................................. 34
Table 2. 2 Current medications..................................................................................................... 35
Figure 2. 1 Bone mineral density in non-demented and early AD groups ................................... 36
Figure 2. 2 Relationship between whole brain volume and whole body bone mineral density in
the non-demented and early AD groups ............................................................................... 37
Chapter 3
Table 3. 1 Sample characteristics.................................................................................................. 54
Table 3. 2 Positive correlations between BMD and grey matter volume in the participants with
AD with adjustment for age and gender ............................................................................... 55
Figure 3. 1 Whole brain VBM results in AD................................................................................ 56
Figure 3. 2 Hypothalamic volume correlates with BMD in AD................................................... 57
Figure 3. 3 Hypothalamic volume and BMD in non-demented.................................................... 58
Figure 3. 4 Hypothalamic volume and BMD in AD..................................................................... 59
Chapter 4
Table 4. 1 Sample characteristics.................................................................................................. 78
Table 4. 2 Summary of literature review ...................................................................................... 79
Figure 4. 1 Correlation between methods ..................................................................................... 80
Figure 4. 2 Bland-Altman agreement between methods............................................................... 81
Figure 4. 3 Face validity ............................................................................................................... 82
xiii
Chapter 5
Table 5. 1 Sample characteristics.................................................................................................. 98
Table 5. 2 Predictors of bone loss ................................................................................................. 99
Figure 5. 1 Two-year bone loss................................................................................................... 100
Figure 5. 2 Bone loss in women and men with and without AD................................................ 101
Figure 5. 3 Vitamin D status in non-demented and AD ............................................................. 102
Figure 5. 4 Correlation of bone loss with vitamin D .................................................................. 103
Figure 5. 5 Correlation of bone loss and hypothalamic atrophy................................................. 104
Chapter 6
Table 6. 1 Sample characteristics at baseline and change over two years .................................. 123
Table 6. 2 Univariate correlates of bone density at baseline .................................................. 12424
Table 6. 3 Univariate correlates of percent change in bone density from baseline ................ 12525
Figure 6. 1 Basic hypothetical model ......................................................................................... 115
Figure 6. 2 Intermediate hypothetical model .......................................................................... 11177
Figure 6. 3 Final results of path analysis .................................................................................... 126
xiv
“One falling leaf is not just one leaf; it means the whole autumn”
D. T. Suzuki
1
Chapter 1
Introduction
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1.1 Alzheimer’s Disease
The prevalence of Alzheimer’s disease (AD) is rising dramatically as the population ages
and is now among the leading causes of death in older people (2008). AD is a progressive
disorder that is characterized by accumulation of neurotoxic beta-amyloid protein (Aβ) plaques
and neurofibrillary tangles in the brain and neurodegeneration. Plaques and tangles form
predominantly in the entorhinal cortex, hippocampus, hypothalamus, basal forebrain and
amygdala. Although the causal role of plaques and tangles in neuronal death and brain atrophy
remains a matter of immense debate, the pathologic diagnosis of AD is associated with high
tangle pathology (Braak stage) and high total percentage area of plaques in the hippocampus
(Burton, Barber et al. 2009). Latter pathological changes in AD are associated with atrophy of
medial temporal lobe and particularly the hippocampus (Jack, Dickson et al. 2002). Brain
atrophy, a sensitive marker of neurodegeneration (Thompson, Hayashi et al. 2003), in AD
progresses in a relatively stereotypical fashion, beginning in the limbic system (i.e., the posterior
cingulate and the hippocampus), progressing to the temporal-parietal cortices followed by the
frontal lobes and late in the disease the occipital lobe and sensorimotor cortices (Thompson,
Hayashi et al. 2007).
Clinical manifestations of AD include memory loss, impaired ability to mentally
manipulate visual information, language deterioration, poor judgment, confusion, restlessness,
and mood swings. While cognitive decline is a clinical hallmark of AD, changes in physical
health are also apparent during the course of AD and include increasing frailty, lower aerobic
capacity, weight loss and gait and motor dysfunction (Kluger, Gianutsos et al. 1997; Barrett-
Connor, Edelstein et al. 1998; Camarda, Camarda et al. 2007; Burns, Cronk et al. 2008).
Eventually AD destroys cognition, personality, physical health and ability to function, greatly
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contributes to disability in older adults and places considerable burden on the health system,
patients, and caregivers.
1.2 Alzheimer’s Disease and Bone Loss
Bone health is an important issue in aging and AD. Osteoporosis–related fractures are
among the major health and socioeconomic concerns in aging. In the USA, 1.5-2 million
fractures, including 325,000 hip fractures, occur annually with an estimated direct cost of $20
billion/year and predicted doubling in number of hip fractures within 30 years. Hip fractures in
older adults result in greater morbidity, disability and premature death (18-33% of hip fracture
patients die within a year). Patients with AD have two to three times higher incidence of
fractures and are more likely to fall compared to cognitively healthy older adults. Importantly,
the relationship between fractures and dementia is independent of falling (Weller and Schatzker
2004). Additionally, individuals with AD have poorer recovery (Buchner and Larson 1987;
Weller 2000; Weller and Schatzker 2004) and higher mortality rates (van Dortmont, Douw et al.
2000) after suffering a hip fracture. For example, survival at 6 months after a hip fracture is up to
4 times lower in those with dementia (Nightingale, Holmes et al. 2001).
Bone mineral density (BMD) is a widely used proxy measure of bone health in clinical
practice and research. BMD, an estimate of bone strength, accounts for 60-70% of bone strength.
Regional (femoral neck, lumbar spine, Ward’s triangle etc.) as well as total body BMD (Schott,
Cormier et al. 1998) measures are strong predictors of bone fractures, and a determining factor in
clinical diagnosis of osteoporosis (Ammann and Rizzoli 2003). Several studies in women
suggest that low BMD is associated with poorer cognitive function and subsequent cognitive
decline (Yaffe, Browner et al. 1999; Lui, Stone et al. 2003) and two times higher risk of
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developing AD (Tan, Seshadri et al. 2005), suggesting that low BMD can be viewed as a risk
factor for AD. The most recently published population study found that lower BMD and
increased rate of bone loss were associated with increased risk of AD in both women and men
(Zhou, Deng et al. 2010). However, there is little data on bone health in individuals with AD. In
a study of women, BMD was reduced in AD compared to cognitively normal females of similar
age, with decreasing BMD in the most severely demented (Sato, Honda et al. 2005). This
evidence suggests that bone loss may be accelerated in AD and BMD may be predictive of AD
progression. Despite the evident association between bone loss and AD, bone health in AD
remains understudied and the mechanisms underlying the association between bone loss and AD
are not well understood.
1.3. Bone Metabolism and Regulation of Bone Remodeling
Two distinct types of bone, cortical and trabecular, comprise the human skeleton and
fulfill its functions. Cortical bone consists of concentric layers of mineralized collagen (matrix)
with embedded osteocytes. Cortical bone comprises 80% of the human skeleton and forms shafts
of long bones such as humerus, femur and tibia, and the surface of flat bones. Trabecular bone
contains interconnecting trabeculae aligned along lines of stress and bone marrow filling out the
spaces. Trabecular bone forms the ends of long bones and the inner parts of flat bones, such as
pelvis, ribs, and vertebrae. Bone is a highly dynamic, metabolically active and responsive tissue.
These qualities are attributed to actions of bone cells. Osteocytes “sense” molecular and
mechanical signals and modulate mineral homeostasis and bone metabolism (or remodeling).
Bone remodeling is maintained through a balance and tight coupling between bone resorption by
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osteoclasts and bone formation by osteoblasts. In adulthood, bone remodeling is a continuous
process of bone tissue turnover that occurs throughout the lifespan.
Multiple factors regulate or mediate this servo system and perturbations of this system
can result in bone loss. The most important and well-studied major modulators of bone health are
calcium, sex steroids, mechanical usage and vitamin D availability. Sex hormone levels are
regulated by the hypothalamic-pituitary-gonadal (HPG) system and reproductive agenda.
Withdrawal of estrogen leads to bone loss. Mechanical usage during physical activity translates
to strain in the bone matrix and modulates bone remodeling. Although the molecular
mechanisms of mechanical load and exercise are not defined, a reduction in bone strain due to
immobilization can lead to severe bone loss, while strenuous physical activity can increase bone
mass (Fredericson, Chew et al. 2007). In addition to major modulators, multiple local and
systemic factors modulate bone health. Systemic growth factors and cytokines, such as insulin-
like growth factor (IGF- 1) and tumor necrosis factor α (TNF-α) also regulate bone remodeling.
Bone cells are able to release certain cytokines, growth factors, gap junction proteins and
transcriptional factors that regulate bone formation and resorption. In addition to local regulatory
function, bone-derived factors that regulate systemic metabolism have been identified. For
example, osteocalcin, a hormone-like peptide that is produced by osteoblasts, is found to be
involved in energy metabolism (Confavreux, Levine et al. 2009; Yadav, Oury et al. 2009).
Octeocalcin regulates energy metabolism by positive effects on pancreatic β-cells proliferation,
insulin secretion and sensitivity (Lee, Sowa et al. 2007).
1.3.1 Vitamin D is mainly synthesized in the skin in an inactive pre- D3 form and is partially
obtained from dietary origin. To be biologically active, D3 has to be first converted to 25 hydroxy
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vitamin D (25 OHD) by the liver-derived enzymes. 25 OHD is a reliable indicator of vitamin D
status. The main function of its fully active form, 1, 25 (OH)2 , is to maintain plasma calcium and
phosphorus levels at physiological levels by regulating intestinal calcium absorption, calcium
storage via skeletal mineralization, and calcium renal reabsorption. The mechanism of action of
the active 1, 25 (OH)2 form is similar to other steroid hormones. Besides bone, vitamin D
receptors (VDR) have been found in the pancreatic β-cells, various precursor cells, skin, thymus
and brain, including hypothalamus (Eyles, Smith et al. 2005). Calcium deficiency because of
poor diet, malabsorption or other pathology leads to bone loss via osteoclast-mediated bone
resorption stimulated by vitamin D in the presence of PTH. Hyperparathyroidism and vitamin D
deficiency can cause bone loss.
1.3.2 Central Regulation of Bone Remodeling: Superimposed upon local and systemic factors
(Zaidi 2007), there is now clear evidence that the CNS directly regulates bone remodeling
through the actions of the hypothalamus through two distinct pathways, the neural and
neurohumoral arms (Harada and Rodan 2003; Takeda 2005).
The neural arm involves hypothalamic control of bone remodeling through sympathetic
nervous system (SNS) output mediated by leptin. The SNS output from the
leptinergic/peptidergic neurons in the ventromedial hypothalamus directly regulates bone
remodeling through activation of β -2 adreno-receptors (β2AR) on the osteoblasts, resulting in
reduced bone formation (Takeda and Karsenty 2008) and increased bone resorption secondary to
the stimulation of pro-resorptive mechanisms (Elefteriou, Ahn et al. 2005). Recent evidence
suggests that additional mediators of leptin’s effects on bone may play a role in this mechanism.
These include serotonin, CART (cocaine amphetamine regulated transcript), Neuromedin U and
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neuropeptide Y. Leptin regulates production of these mediators in CNS including the
hypothalamus. (Elefteriou, Ahn et al. 2005; Singh, Elefteriou et al. 2008; Yadav, Oury et al.
2009). There is evidence that sympathetic output from the hypothalamus via the neural arm has
greater effects on regulation of bone remodeling than the actions of sex steroids (Elefteriou,
Takeda et al. 2004; Pogoda, Egermann et al. 2006) or mechanical use (Martin, David et al.
2008).
Leptin, a cytokine-like 16-kDa protein that is synthesized mostly by white adipose tissue,
is a key mediator of neural control of bone remodeling through the neural arm. Leptin appears to
regulate a number of physiological functions such as feeding, fat storage and utilization, energy
metabolism, and bone remodeling. The main effects are exerted by leptin acting in the brain.
There is no evidence that leptin is produced in the brain (Elefteriou, Takeda et al. 2004); it enters
the brain from the periphery in a unidirectional fashion (Takeda, Elefteriou et al. 2002). The
actions of leptin are executed through binding of leptin to its receptor (Ob-R) that belongs to the
family of class 1 cytokine receptors and exists in at least six isoforms. The Ob-R is present in the
arcuate, dorsomedial and ventromedial hypothalamic nuclei, hippocampus, cortex and
cerebellum (Harvey 2007) and many peripheral tissues. The role of leptin as a key regulator of
bone remodeling is established in a series of animal experiments (Ducy, Amling et al. 2000;
Patel and Elefteriou 2007). Central leptin acts on leptinergic/peptidergic neurons (different from
the neuronal network involved in feeding) in the ventromedial hypothalamus. Through activation
of SNS and β2AR on the osteoblasts, central leptin inhibits bone formation (Ducy, Amling et al.
2000; Sato, Takeda et al. 2001; Takeda and Karsenty 2008) and increases bone resorption
secondary to the stimulation of pro-resorptive mechanisms (Elefteriou, Ahn et al. 2005).
Negative effects of high levels of both peripheral and central leptin on mostly cortical
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bone (Martin, David et al. 2008) are consistently reported in animal models (Guidobono, Pagani
et al. 2006; Martin, David et al. 2007). Additionally, high levels of central leptin dramatically
decrease circulating IGF-1 and stimulate SNS in animals (Martin, David et al. 2008). The central
hypothalamic relay is confirmed as the major regulatory mechanism of bone remodeling with
peripheral levels of leptin modifying its activity (Elefteriou, Takeda et al. 2004). Importantly,
observations in lipodystrophic mice that display a high bone mass phenotype and patients with
congenital lipodystrophy that display low to undetectable levels of leptin and premature bone
formation suggest that leptin’s regulation of bone remodeling is preserved in humans (Elefteriou,
Takeda et al. 2004). The role of leptin in bone remodeling in humans, however, needs to be
further clarified. Current reports on association between leptin levels and BMD in humans are
highly contradictory (Cock and Auwerx 2003) and range from negative (Oh, Lee et al. 2005;
Maimoun, Coste et al. 2008) or no association (Di Carlo, Tommaselli et al. 2007; Peng, Xie et al.
2008) to positive relationship (Zoico, Zamboni et al. 2008; Oguz, Tapisiz et al. 2009), suggesting
a clear need for further study.
Sympathetic nervous system (SNS) mediates the central leptin-dependent hypothalamic
control of bone remodeling via β2AR in osteoblasts (neural arm). This mechanism was
confirmed by data from various genetic animal model studies, discovery of β-2 adrenergic (but
not β-1 or β-3) receptors on osteoblasts (Takeda 2005), and animal and human studies on β -
blockers and adrenergic agonists. Animal studies demonstrated, for example, that: 1) leptin-
deficient mice (ob/ob) have low sympathetic tone accompanied by high bone mass; 2) both
stimulation of ventromedial hypothalamic neurons and central leptin infusions stimulate the
SNS; 3) β2AR deficient mice have increased bone mass, bone formation rates, and numbers of
osteoblasts and are resistant to central leptin infusions (Elefteriou, Ahn et al. 2005; Takeda and
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Karsenty 2008). In line with these observations, use of β -blockers in mice and rats led to
increased bone mass (Minkowitz, Boskey et al. 1991; Takeda, Elefteriou et al. 2002), while use
of adrenergic agonists led to bone loss (Bonnet, Benhamou et al. 2005). Human studies have
demonstrated a reduced fracture risk and increased BMD in β -blocker users (Turker, Karatosun
et al. 2006; Wiens, Etminan et al. 2006; Meisinger, Heier et al. 2007). The SNS pathway is the
only identified downstream signaling pathway for central leptin function in bone remodeling.
Therefore, it is plausible that AD-related neurodegeneration, in particular affecting the
hypothalamus, may disrupt central mechanisms regulating bone mass and contribute to bone loss
in AD.
The neurohumoral arm involves hypothalamic control of the anterior pituitary hormones,
such as thyroid stimulating hormone (TSH), follicle-stimulating hormone (FSH) and growth
hormone (GH). TSH and FSH mediate bone remodeling directly through their receptors in bone
cells and additionally, through secretion of thyroxin and sex hormones from target endocrine
organs. GH and IGF-1 are anabolic hormones necessary in bone development and maintenance
of bone mass in adulthood (Giustina, Mazziotti et al. 2008).
Growth hormone (GH) or somatotropin is a single-chain 191-amino-acid protein secreted
by the anterior pituitary. Its secretion is primarily controlled by the hypothalamus. Hypothalamic
GH-releasing hormone (GHRH) and somatotropin release-inhibiting factor (SRIF, somatostatin)
directly regulate GH secretion. GH executes its anabolic action on bone mainly through IGF-1.
Insulin-like growth factor 1 (IGF-1) is a 70-amino acid hormone secreted by a wide range
of tissues. The majority of IGF-1 is secreted by the liver under the control of GH. IGF-1 plays an
important role in the stimulation of osteoblastic function, bone matrix collagen synthesis and
bone formation. IGF-1 exerts a direct inhibitory effect on GH via long-loop feedback (Gahete,
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Duran-Prado et al. 2009). Both GH and IGF-1 stimulate trabecular and cortical bone formation,
however with greater effects on cortical bone (Murray, Adams et al. 2006).
In summary, while the central hypothalamic control of bone remodeling is established
and well studied in animals, bone remodeling in conditions that directly affect brain in humans,
such as neurodegeneration in AD, has not been investigated.
1. 4 The Hypothalamus
The hypothalamus, a part of the limbic system, has extensive connections within the
brain and modulates a variety of regulatory processes including appetite, energy expenditure,
sleep and wakefulness and stress responses, all of which are disturbed in AD (Chouinard,
Lavigne et al. 1998; Volicer, Harper et al. 2001). Additionally, the hypothalamus plays a role in
memory through connections with the hippocampal formation. Recent findings have confirmed
that the hypothalamus is the main regulatory center in the central control of bone remodeling
(Patel and Elefteriou 2007). However, bone remodeling in conditions that directly affect the
hypothalamus is not well studied. AD is characterized by progressive brain atrophy that begins in
the limbic system (Thompson, Hayashi et al. 2007). Evidence of AD-related limbic atrophy in
the hypothalamus, however, is limited and to our knowledge has been reported in one cross-
sectional study using manual tracing of the structure (Callen, Black et al. 2001). Measuring
longitudinal changes in the hypothalamic volume in relation to function, such as maintaining
bone mass, in patients with AD and non-demented elderly may provide evidence that
hypothalamic atrophy may be one of the mechanisms of bone loss in AD.
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1.5 The Hypothalamus: Changes in AD
Pathological changes occur in the hypothalamus in AD and include profound neuronal
loss (de Lacalle, Iraizoz et al. 1993), abundant AD plaques and tau tangles (Standaert, Lee et al.
1991) and overall volume loss (Callen, Black et al. 2001). AD is associated with clinical
symptoms referable to hypothalamic dysfunction including sleep and circadian rhythm
disturbances(Wu and Swaab 2005), alterations in appetite and energy expenditure, and body
wasting (Deshmukh and Deshmukh 1990; Ferrari, Arcaini et al. 2000). There is abundant
evidence of AD-related dysfunction in both the neurohumoral and neural arms. Dysfunction of
the hypothalamo-pituitary axis and activity of the SNS are reported in AD. For instance, GH and
IGF-I levels (Alvarez, Cacabelos et al. 2007; Gomez 2008) are reduced in AD while interestingly
a number of other hypothalamic factors are increased in AD, including corticotropin-releasing
hormone (CRH)(Raadsheer, van Heerikhuize et al. 1995), cortisol (Peskind, Wilkinson et al.
2001; Rasmuson, Andrew et al. 2001), FSH (Bowen, Isley et al. 2000; Meethal, Smith et al.
2005), and TSH (de Jong, Masaki et al. 2007). Additionally, several studies demonstrate
evidence of increased sympathetic activity (Pascualy, Petrie et al. 2000) including increased
brain noradrenergic activity and elevated serum and cerebrospinal fluid levels of norepinephrine
(Raskind, Peskind et al. 1984; Elrod, Peskind et al. 1997; Raskind, Peskind et al. 1999). Why
increased activity has been observed in some aspects of the hypothalamic-pituitary axis in AD
remains unclear but may be related to disturbed negative feedback (Elgh, Lindqvist Astot et al.
2006) while increased SNS activity may be related to overcompensation of remaining
noradrenergic neurons in response to profound noradrenergic neuronal loss (Szot, Leverenz et al.
2000). New evidence suggests that leptin plays a role in AD pathology (Fewlass, Noboa et al.
2004) and is associated with cognitive function (Gunstad, Spitznagel et al. 2008; Holden,
12
Lindquist et al. 2008) and brain atrophy (Narita, Kosaka et al. 2008). Converging animal,
clinical, pathological and neuroimaging data suggest that it is plausible that AD-related
neurodegeneration, in particular affecting the hypothalamus, may disrupt central mechanisms
regulating bone mass and contribute to bone loss in early AD.
1.6 Neuroimaging
Magnetic resonance imaging (MRI) based volumetric studies are increasingly being
employed as surrogate outcome measures of disease. For example, hippocampal volume loss is
considered a valid biomarker of AD neuropathology. Other sensitive markers of brain aging
include whole brain volume as a marker of brain atrophy. The clinical importance of these
measures is becoming increasingly clear given their association with reduced cognition,
increased dementia risk, and strong relationships with age (Masdeu and Pascual 2008). The
development of sensitive neuroimaging markers of brain aging and disease is a significant
advance in understanding the mechanisms of brain aging and a foundation for future
investigations of mechanisms of cognitive and centrally regulated physical function decline.
High-resolution magnetic resonance imaging allows an in vivo assessment of structural brain
changes. MRI, with employment of modern neuroimaging analysis tools, has the potential to
capture structural changes in the hypothalamus.
Voxel-based morphometry (VBM) has gained substantial popularity due to its unique
quality of utilizing digital information available for each voxel and transforming it to estimation
of grey and white matter volumes. VBM is a powerful technique for systematic evaluation of the
whole brain and statistical analysis that also allows measuring volumes of grey and white matter
in semi-automated region-of-interest (ROI) approach. Optimized VBM with the Wake Forest
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University Pickatlas (WFU) toolbox also automatically generates segmented atlas ROI templates
and summarizes all the voxel values into grey or white matter volumes within each ROI (Good,
Johnsrude et al. 2001). The advantage of VBM as an automated technique is that it provides a
perfectly reproducible result on a given data set.
1.7 Potential Mechanisms for Relationship between Bone Mass and AD
Multiple factors have been postulated to explain the association between bone loss and
cognitive decline, including estrogen exposure, apolipoprotein E4, depression and lifestyle
factors such as physical activity, nutritional, dietary, and environmental factors. Overarching,
however, is hypothalamic control over many of the factors that have been identified to modulate
bone health. AD is associated with extensive hypothalamic structural damage and hypothalamic
dysfunction, thus, it is plausible that hypothalamic damage could result in clinically evident bone
loss, given the important role the hypothalamus plays in regulating bone mass. Additionally, AD
exacerbates age related processes such as physical activity decline, hormonal changes and energy
expenditure all found to contribute to bone loss. Therefore, the neurodegeneration and profound
brain and hypothalamic atrophy may directly disrupt central neuronal network involved in
regulation of bone remodeling and indirectly contribute to bone loss via negative effects on other
hypothalamic functions (energy expenditure, gonadal function, PTH, vitamin D and Ca
metabolism).
1.8 Significance of Present Work
Despite the fact that bone loss has been long associated with AD no studies have
systematically assessed bone loss in AD and to date there has been no specific hypothesis that
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comprehensively explains association of bone loss with AD. The main hypothesis of this study is
that neurodegeneration disrupts neural and neurohumoral mechanisms of central control of
bone remodeling leading to bone loss secondary to a neurodegenerative disease, such as AD.
The fact that the hypothalamus, a key regulatory region in the central control of bone
remodeling, is affected by AD pathology has been previously overlooked in attempts to explain
the association between AD and bone loss. Thus, in this work we systematically evaluated bone
health in early AD and used a novel assessment of neurodegeneration and atrophy of the brain
and hypothalamus as one of the mechanisms of bone loss secondary to neurodegeneration.
Additionally, bone loss was investigated in the association with progression of AD and brain
atrophy. The results of the study contribute to a significant question on whether BMD and bone
loss can be used as a predictor of AD progression.
Moreover, we are the first to test a theoretical model of mechanisms of bone loss in
neurodegeneration in humans that brings together the hypothalamic neural and neurohumoral
regulators of bone remodeling, clinical outcome measures of bone loss, neuroimaging markers of
hypothalamic atrophy in a context of shared modifiable risk factors for AD and osteoporosis.
Understanding the physiological mechanisms underlying bone loss and the role of
neurodegeneration is relevant to developing effective preventive strategies and therapeutic
interventions for bone loss in aging population affected by AD and other neurodegenerative
diseases.
1.9 Specific Aims and Statement of Hypotheses
The main purpose of this project was to study effects of neurodegeneration (measured by
neuroimaging markers) on central control of bone mass as a potential mechanism underlying the
association between bone loss and AD. Three central aims directed this research.
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Specific Aim 1: Characterize bone loss over two years in early AD.
Despite the fact that bone loss has been long associated with AD, no studies
systematically assessed bone loss in AD and to date there has been no specific hypothesis that
comprehensively explains association of bone loss with AD. Based on the evidence that, in
addition to age (McCalden, McGeough et al. 1993), activation of central neural regulatory
mechanisms has greater negative effects on cortical bone (Martin, David et al. 2008), we
hypothesized that if systematically assessed, rates of bone loss at the skeletal sites of cortical
bone, such as total body and legs, in AD would exceed bone loss in the control group. Bone loss
at trabecular skeletal sites, such as the spine or pelvis, would be comparable between the groups.
In the Chapter 2 we demonstrate that in a cross-sectional study low total body BMD (80%
cortical bone) was observed in both men and women with AD. In a longitudinal study (Chapter
5), we demonstrate that not only was BMD lower at the baseline but the rates of bone loss were
higher in AD at the skeletal sites of cortical bone (total body and legs), but not at the trabecular
skeletal sites (the spine or pelvis).
Specific Aim 2: Assess the relationship of bone mass with neuroimaging markers of
neurodegeneration including hypothalamic atrophy in a context of shared modifiable risk
factors for AD and osteoporosis.
The evidence that AD is associated with brain pathology in the key regulatory regions in
the brain including the hypothalamus has been previously overlooked in attempts to explain the
association between AD and bone loss. We hypothesized that it is biologically plausible to see an
association between bone loss and neuroimaging markers of neurodegeneration, including
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hypothalamic atrophy. In the Chapters 3 and 4, we demonstrate that indeed, participants with AD
had smaller hypothalamic volumes, suggestive of hypothalamic atrophy. Lower BMD was
associated with lower total brain and hypothalamic volumes in early AD (Chapter 2&3) but not
in controls. In the longitudinal assessment (Chapter 5), age, female gender and decline in
physical activity were associated with bone loss in non-demented older group, while bone loss in
AD was associated with vitamin D deficiency and atrophy of the hypothalamus.
AIM 3: Determine the relationship of bone mass with neural (leptin) and neurohumoral
(growth hormone and IGF-1) mediators of hypothalamic control of bone remodeling and
whether these relationships change in neurodegeneration.
Central nervous system (CNS) directly regulates bone remodeling through the actions of
the hypothalamus via two distinct pathways, the neurohumoral (through the neurohormones) and
direct neural (through SNS mediated by leptin) arms (Takeda 2005). Therefore, we hypothesized
that accelerated bone loss will be associated with changes in mediators of hypothalamic control
of bone remodeling driven by the hypothalamic volume loss in AD. In Chapter 6, hypothalamic
atrophy and changes in levels of key hypothalamic mediators of bone metabolism were assessed
in relation to bone loss using causal modeling statistical analysis. The model demonstrated that
hypothalamic atrophy had a direct and a small indirect effect on bone loss. Hypothalamic
atrophy was associated with increase in leptin in AD. Increase in leptin was associated with a
decline in IGF-1 levels over two years in individuals with AD.
Five manuscripts based on the work presented in this dissertation have been published
(2), submitted (1) or will be submitted for publication (2). The first manuscript was based on a
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cross-sectional data with an aim of examining the bone density in early AD and its relationships
with neuromaging and clinical marker of AD and comparing to non-demented controls (Chapter
2; published in the Journal of Alzheimer’s Disease). The second manuscript utilized a smaller
sub-sample of the data and looked at specific relationships between volumes of gray matter
including the hypothalamus and bone density in participants with early AD and non-demented
controls using neuroimaging analysis (Chapter 3; published in the Journal of Alzheimer’s
Disease). The third manuscript utilized randomly selected sub-sample of 40 participants to
compare performance of two methods currently used in neuroimaging research for assessment of
hypothalamic volume (Chapter 4; submitted to NeuroImage). The fourth manuscript utilized
longitudinal data to look at rates and predictors of bone loss over two years in participants with
early AD and non-demented controls (Chapter 5; to be submitted). The fifth manuscript is an
exploratory study of potential mechanisms that may underlie the association of bone loss and
hypothalamic atrophy in early AD using casual modeling statistical technique (Chapter 6; to be
submitted).
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Chapter 2 Preface
In Chapter 1, previously published work in the literature describing the relationship
between bone health and AD was presented, largely from population studies and studies in
severely demented women. While these studies provide important information to the field, some
methodological limitations may drive the observed relationship. For example, AD and bone loss
share numerous common risk factors. High level of these risk factors in the general population
may simply increase the odds of co-occurrence of AD and bone loss. The relationship between
AD and bone loss in severely demented may be potentially explained by malnutrition or reduced
activity (e.g., bedridden state). Additionally, despite the evident relationship between poor bone
health and AD, no studies have explored a relationship between bone density and brain structure
and cognition.
In Chapter 2, we sought to explore the relationship between bone density and clinical and
neuroimaging markers of AD in a cohort of community-dwelling older men and women without
cognitive deficits and diagnosed with very early stages of AD, all of whom were otherwise
relatively healthy.
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Chapter 2
Bone Density and Brain Atrophy in Early Alzheimer Disease
Loskutova N, Honea R, Vidoni E, Brooks W, Burns J: “Bone Density and Brain Atrophy in
Early Alzheimer Disease” 2009, Journal of Alzheimer’s Disease 18, 777-785
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2.1 ABSTRACT
Studies suggest a link between bone loss and Alzheimer’s disease. To examine bone
mineral density (BMD) in early Alzheimer’s disease (AD) and its relationship to brain structure
and cognition we evaluated 71 patients with early stage AD (Clinical Dementia Rating (CDR)
0.5 and 1) and 69 non-demented elderly control participants (CDR 0). Measures included whole
body BMD by dual energy x-ray absorptiometry (DXA) and normalized whole brain volumes
computed from structural MRI scans. Cognition was assessed with a standard
neuropsychological test battery. Mean BMD was lower in the early AD group (1.11 ± 0.13)
compared to the non-demented control group (1.16 ± 0.12, p=0.02), independent of age, sex,
habitual physical activity, smoking, depression, estrogen replacement, and apolipoprotein E4
carrier status. In the early AD group, BMD was related to whole brain volume (b=0.18, p=0.03).
BMD was also associated with cognitive performance, primarily in tests of memory (logical
memory [b=0.15, p=0.04], delayed logical memory [b=0.16, p=0.02], and the selective
reminding task - free recall [b=0.18, p=0.009]). BMD is reduced in the earliest clinical stages of
AD and associated with brain atrophy and memory decline, suggesting that central mechanisms
may contribute to bone loss in early Alzheimer’s disease.
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2.2 INTRODUCTION
The prevalence of Alzheimer’s disease (AD) is rising dramatically as the population ages
and is now among the leading causes of death in older people (2008). While cognitive decline is
a clinical hallmark of AD, changes in physical health are also apparent during the course of AD
and include increasing frailty, lower aerobic capacity, weight loss and gait and motor
dysfunction (Kluger, Gianutsos et al. 1997; Barrett-Connor, Edelstein et al. 1998; Camarda,
Camarda et al. 2007; Burns, Cronk et al. 2008).
Bone health is an important issue in AD given a higher risk of falls and increased
incidence of fractures in individuals with AD compared to cognitively healthy older adults.
Additionally, individuals with AD have poorer recovery (Buchner and Larson 1987; Weller
2000; Weller and Schatzker 2004) and higher mortality rates (van Dortmont, Douw et al. 2000)
after suffering a hip fracture. While several studies in women suggest that low bone mineral
density (BMD) is associated with higher risk of developing AD (Tan, Seshadri et al. 2005) and
cognitive decline (Yaffe, Browner et al. 1999; Lui, Stone et al. 2003), there is little data on bone
health in individuals with AD. In a study of women, BMD was reduced in AD compared to
cognitively normal females of similar age, with decreasing BMD in the most severely demented
(Sato, Honda et al. 2005), suggesting that bone loss may be accelerated in AD. Although this
evidence suggests a link between AD and BMD (Tysiewicz-Dudek, Pietraszkiewicz et al. 2008)
little is known about how early in the disease bone loss might occur and whether bone loss is
observed in men with AD.
Multiple factors have been postulated to explain the association between bone loss and
cognitive decline in women, including estrogen exposure, apolipoprotein E4, depression and
lifestyle factors such as physical activity, nutritional, dietary, and environmental factors.
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Accumulating evidence also suggests that the central nervous system directly regulates bone
health through actions primarily orchestrated by the hypothalamus (Harada and Rodan 2003;
Takeda 2005; Zaidi 2007), a structure affected early in the AD process (Raskind, Peskind et al.
1999; Callen, Black et al. 2001). However, no studies have evaluated bone health in relation to
cognition and brain structure. The purpose of this study was to compare bone health in the
earliest clinical stages of AD with non-demented aging and to determine whether BMD is
associated with cognitive performance and brain atrophy, which is used as a marker of
neurodegeneration. We hypothesized that bone density would be lower in early AD and that
reduced BMD would be associated with brain atrophy and cognitive decline. Understanding the
association of bone loss and AD, in the context of other BMD-modifying factors, may provide
strategies for developing effective prevention and treatment of osteoporosis and could ease the
burden associated with bone fractures in AD.
2.3 MATERIALS AND METHODS
Sample and recruitment
71 patients with early-stage AD (Clinical Dementia Rating (CDR) 0.5, n=57 and CDR
1.0, n=14) and 69 non-demented elderly control participants (CDR 0) were enrolled in the
University of Kansas Brain Aging Project. Participants were recruited from a referral based
memory clinic and by media appeals. Signed institutionally-approved informed consent was
obtained prior to enrollment from all participants or their legal representatives and the informants
who know the participants well and served as the collateral source. Participants with a history of
neurologic disease other than AD, diabetes mellitus, ischemic heart disease, schizophrenia, major
depression, contraindications to MRI, and a history of alcohol abuse were excluded from the
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study. Clinical assessment methodology and clinical and neurological characteristics of the study
participants have been presented previously(Burns, Cronk et al. 2008).
Whole body bone mineral density
Dual energy x-ray absorptiometry (DXA) (Prodigy fan-beam densitometer, Lunar Corp.,
GE Medical Systems, Madison, WI) was used to determine total skeleton BMD. We used whole
body BMD as a measure of global bone health. Whole body BMD gives a comprehensive view
of the whole skeleton (Blake, Herd et al. 2000) and is mostly determined by cortical bone (Szulc,
Marchand et al. 2000). Cortical bone porosity and decline in mechanical properties are reported
in aging (McCalden, McGeough et al. 1993) and associated with fractures. Cortical bone density
decline is found to be more specific than trabecular BMD for the older population and may play
an important role in bone fragility in elderly (Uusi-Rasi, Sievanen et al. 2007; Seeman 2008).
Magnetic resonance imaging
Structural MRI data were obtained at the Hoglund Brain Imaging Center with a 3.0 T
Allegra MR scanner (Siemens Medical Solutions, Erlangen, Germany). T1 weighted
magnetization prepared rapid gradient echo (MP-RAGE) sequence (1x1x1mm3 voxels; TR =
2500ms, TE = 4.38ms, TI = 1100ms, FOV 256x256cm2 with 18% oversample, flip angle 8
degrees) was performed for high resolution structural analysis. We used FMRIB Software
Library (FSL; www.fmrib.ox.ac.uk/fsl) for computing whole brain volume. Each image was
preprocessed and skull-stripped with Brain Extraction Tool (BET). Next, images were
normalized by registration to the Montreal Neuroimaging Institute (MNI) average 152 template
and then segmented into white, gray matter and CSF with FMRIB’s Automated Segmentation
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Tool. Since brain volumes differ between sexes, brain volumes were normalized to intracranial
volume for each participant summing white and gray matter volumes and presented as percent of
intracranial volume (% ICV). Image processing was conducted with Laboratory of
Neuroimaging Pipeline (University of California, Los Angeles, www.pipeline .loni.ucla.edu).
Normalized brain volumes were not related to sex (r=0.09, p=0.3). Normalized brain volume was
used as a sensitive marker of brain atrophy(Battaglini, Smith et al. 2008).
Neuropsychological assessment
We administered a psychometric battery consisting of standard measures of memory
(WMS-R Logical Memory I and II(Wechsler and Stone 1973), Free and Cued Selective
Reminding Task (Grober, Buschke et al. 1988)), language (Boston Naming Test–15 item
(Goodglass and Kaplan 1983)), working memory (WMS III Digit Span Forwards and Backwards
(Wechsler and Stone 1973) WAIS Letter-number sequencing (Wechsler 1955)), executive
function (Trailmaking A and B (Armitage 1946), Verbal Fluency [animals, fruits and
vegetables](Hänninen, Reinikainen et al. 1994), and Stroop Color-Word Test(Stroop 1935)), and
visuospatial ability (WAIS Block Design(Wechsler 1955)) as reported previously (Burns, Cronk
et al. 2008). We created a composite measure of global cognition by first, converting individual
test scores for each participant to z-scores using a reference sample of non-demented older adults
(n=83) and then computing the mean of all z-scores for each participant. Mini-Mental State
Examination (MMSE) was administered as a standard measure of global cognition (Folstein,
Folstein et al. 1975).
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Other potential modifiers
Habitual physical activity level was assessed using the Physical Activity Scale for the
Elderly (PASE) (Washburn, McAuley et al. 1999). The PASE scores were collected from the
study participants and their collateral sources. The modified Physical Performance Test (PPT)
was administered as a physical frailty assessment (Burns, Cronk et al. 2008). Geriatric
Depression Scale (GDS) was administered to study participants and their collateral source to
assess depressive signs(Burke, Houston et al. 1989). Apolipoprotein E (ApoE) genotypes were
obtained using restriction enzyme isotyping (Hixson and Vernier 1990). Self-reported tobacco
history was collected along with demographic characteristics for each participant. Tobacco use
for those with a present or past history of smoking was calculated in Pack Years. Participants
were divided into three groups (never smoked, smoked more that 100 cigarettes previously but
not in last 30 days, currently smoking) for statistical analysis. DXA was used to assess fat mass
and percent body fat of the participants dressed in a hospital gown. Body weight in kg and height
in cm were recorded and body mass index (BMI, kg/m2) was calculated for each study
participant. Total cholesterol, triglycerides, high-density (HDL) and low-density (LDL)
lipoproteins levels were assessed in fasting venous blood samples as described previously
(Burns, Donnelly et al. 2007).
Self-reported medication use was collected from the collateral source by a nurse
clinician. Hormone-replacement therapy (HRT) medications (estrogen, testosterone and selective
estrogen receptor modulators), thyroid hormone replacement, bisphosphonates, beta-blockers,
vitamin D and calcium were considered as bone affecting. The total number of participants in
each group that reported use of medications with primary or potential effects on bone health for
two or more weeks prior to the study enrollment was recorded.
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Statistical analyses
Statistical analyses were conducted using SPSS 16.0 software package (SPSS Inc.,
Chicago, Ill). Continuous variables were summarized as means ± standard deviation (SD) and
categorical variables were summarized by percent. Independent samples t-tests were used for
analyzing group differences in continuous variables and chi-square statistics were used for
categorical data. The general linear model was used for assessing effects of dementia and
additional potential modifiers (habitual physical activity (PASE), signs of depression (GDS),
frailty (PPT), genetic component (ApoE4), use of bone affecting medications and tobacco
history) on BMD, with age and sex included as primary covariates. We added an interaction term
to examine whether the association of BMD and dementia was modified by sex (dementia*sex).
An association of BMD with age was assessed with Pearson r coefficient of correlation. An
association of BMD with past or present history of smoking (Pack Years) was assessed by partial
correlation controlled for age and sex. We used a stepwise linear regression model to examine: 1)
the association of BMD with whole brain volume, first controlling for age and sex followed by
additional models assessing the effect of other covariates on the relationship between BMD and
whole brain volume, and 2) the association of BMD with cognitive measures, controlling for age
and sex and the effect of the potential modifiers on this association. Assumptions for linearity,
normality, equal variance and homoscedasticity of errors were examined and adequately met.
Statistical significance was tested at a=0.05.
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2.4 RESULTS
Sample description
Demographic and clinical characteristics of the participants in the non-demented (n=69)
and early AD groups (n=71) are summarized in Table 1. Early AD and non-demented groups
were similar in age (mean age 74.1±6.8 years) and sex distributions. Average BMI, percent body
fat, and serum levels of total cholesterol, triglycerides, HDL and LDL did not differ between
groups. As expected, participants in the early AD group had mild global cognitive impairment,
lower level of habitual physical activity (PASE), higher frailty scores (PPT) and more depressive
signs (GDS). Participants with early AD were more likely to carry the ApoE4 allele than
controls. Brain atrophy was evident in the early AD group. The early AD group had significantly
smaller mean normalized whole brain volume than the non-demented group. Whole brain
volume was significantly associated with MMSE score (r=0.42, p<0.001), our composite
measure of global cognition (r=0.47, p<0.001), and dementia severity (CDR Box score, r=-0.44,
p<0.001) after controlling for age and sex.
The groups did not differ in the use of medications with primary or potential bone
affecting qualities. Table 2 shows the percentage of participants reporting prolonged use of
hormone replacement medications, bisphosphonates, thyroid hormone replacement, beta-
blockers, vitamin D, and calcium supplements in each group.
Bone mineral density and dementia status
Mean whole body BMD was lower in the early AD group (1.11 ± 0.13) compared to the
non-demented control group (1.16 ± 0.12, p=0.02). As expected, BMD decreased with age (r=-
0.21, p=0.01) and was lower in females (1.08± 0.10) than in males (1.21± 0.12, p<0.001).
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We next used the general linear model to assess the role of dementia status on BMD
while controlling for age, sex, and additional covariates. After controlling for age and sex,
individuals with AD had lower BMD than non-demented individuals (b1=-0.04, p=0.03). There
was no interaction between dementia status and sex (dementia*sex, p=0.71) suggesting that AD-
related BMD differences were similar in men and women (Figure 1).
Bone mineral density and additional modifiers
Additional modifiers (physical activity (PASE), frailty (PPT), signs of depression (GDS),
genetic makeup (ApoE4) and use of bone affecting medications) were not related to BMD. There
were no significant effects of smoking history on BMD (p=0.46) after controlling for age and sex
and no dementia*smoking history interaction (p=0.75). There was no association between Pack
Years and whole body BMD after controlling for age and sex in participants who are currently
smoking and used to smoke in either early AD or non-demented groups.
Bone mineral density and whole brain volume
We specifically tested the hypothesis that brain atrophy was associated with BMD. First,
we examined the association of BMD with whole brain volume in the entire cohort using
stepwise linear regression analysis with age and sex as covariates. Higher BMD was associated
with larger brain volumes, i.e. less brain atrophy (b=0.18, p=0.03). Age and sex accounted for
28.1% of the variance with whole brain volume explaining an additional 7.6% of the variance.
Given that group differences in brain volume and BMD may explain this relationship we
next examined the association of brain volume with BMD in the early AD and non-demented
groups separately. A scatterplot of whole brain volume and age- and sex-adjusted BMD is
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presented in Figure 2. In early AD, whole brain volume was associated with BMD (b=0.3,
p=0.004), explaining 8.8% of variance of BMD after controlling for age (non-significant) and
sex (b=0.53, p<0.001, 26.2 % of variance of BMD explained). In the non-demented group, whole
brain volume was not associated with BMD after controlling for age and sex.
Because bone health can be modified by multiple factors, we repeated a series of
regression analyses to examine the influence of potential modifiers on the observed BMD -
whole brain volume relationship. All models controlled for age and sex. Potential modifying
factors such as habitual physical activity (PASE), frailty (PPT), depressive signs (GDS),
Apolipoprotein E4 allele status (ApoE4 carriers vs. non-carriers), use of bone affecting
medications and smoking history were each added to the linear regression model, but none
attenuated the bone density-whole brain volume relationship.
Bone mineral density and cognitive performance
In the entire cohort, BMD was not associated with our composite measure of global
cognition or MMSE performance. BMD was positively associated with performance on logical
memory (b=0.15, p=0.04), delayed logical memory (b=0.16, p=0.02), and the selective
reminding task (b=0.18, p=0.009) after controlling for age and sex. Addition of any of the
potential modifying factors to the regression model did not attenuate the bone-density-cognitive
performance relationship. Within-group analyses were conducted next to minimize the effect of
group differences in BMD and cognitive performance. In the early AD group, BMD remained
associated with logical memory (b=0.25, p=0.01), delayed logical memory (b=0.27, p=0.009),
and the selective reminding task (b=0.25, p=0.02). Measures of dementia severity (CDR and
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CDR box score) were not related to BMD. In non-demented participants, BMD was not
associated with performance on any cognitive measures.
2.5 DISCUSSION
The results of the study suggest that BMD is reduced in the earliest clinical stages of AD
in both men and women. Additionally, BMD was related to whole brain volume and memory
performance in AD, with higher BMD associated with higher whole brain volume (less brain
atrophy) and better memory performance. These results suggest that AD-related brain changes
may affect bone remodeling or that bone loss and AD may share common biological
mechanisms.
There is evidence that major factors contributing to bone loss are associated with AD
though it remains unclear whether alterations in these factors are a cause or a consequence of
AD. BMD has been viewed as a proxy for cumulative estrogen exposure in women and the
BMD-cognition relationship has been interpreted as evidence for a link between estrogen and
cognition (Yaffe, Browner et al. 1999). Although we did not specifically measure estrogen
levels, our observation of reduced BMD in men with AD and more recent clinical trial evidence
of an increased risk of dementia in estrogen users suggests alternative mechanisms may be
responsible for the link between bone loss and AD (Shumaker, Legault et al. 2003).
Some epidemiological studies suggest dietary factors may play a role in AD risk
(Scarmeas, Stern et al. 2006; Barberger-Gateau, Raffaitin et al. 2007). Though, the role of dietary
protein and fat in bone health is still a matter of debate, animal (Mardon, Habauzit et al. 2008)
and human (Ilich, Brownbill et al. 2003; Carlsson, Tidermark et al. 2005; Coin, Perissinotto et al.
2008) studies show that adequate energy and protein provision is essential for preservation of
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skeletal health in elderly. Decreased food intake and changes in dietary patterns may occur in
AD (Munoz, Agudelo et al. 2006; Smith and Greenwood 2008) and could potentially explain
lower bone density in the AD group (Sanlier 2008). In addition to dietary deficiencies in
microelements and nutrients, disturbances in microelement metabolism and exposure to high
concentrations of some minerals are associated with both low bone mass (Lacka-Gazdzik, Klosa
et al. 2005) and AD (Shcherbatykh and Carpenter 2007). High levels of trace elements in the
brains of AD patients are associated with oxidative damage (Cornett, Markesbery et al. 1998), a
potential etiologic mechanism of AD.
Although, diet was not assessed in the study participants (Bianco, Filippi et al. 2008), our
early AD cohort was similar in BMI and percent body fat indicating that AD participants were
not underweight (Sergi, Perissinotto et al. 2005). Serum levels of total cholesterol, triglycerides,
HDL and LDL in the early AD group did not differ from non-demented controls, indirectly
suggesting that their global nutritional status was similar to the non-demented older adults
(Ibrahim, Eltom et al. 1994; Hrnciarikova, Hyspler et al. 2009).
The ApoE4 allele has also been associated with bone loss (Lindsay, Laurin et al. 2002;
Zajickova, Zofkova et al. 2003). Our analyses were unchanged when controlling for ApoE4
carrier status suggesting that ApoE4 does not mediate this relationship, consistent with the
findings of other studies (Efstathiadou, Koukoulis et al. 2004; Schoofs, van der Klift et al. 2004).
Our data raise the possibility that the relationship between bone loss and Apoe4 in other studies
of non-demented older women may have been driven by the likelihood of a higher prevalence of
unrecognized, preclinical AD in the ApoE4 cohort.
Physical activity is an important modulator of bone mass, though its effect on bone mass
may be attenuated in older adults (Kemmler, Weineck et al. 2004). Our early AD cohort
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demonstrated significant reductions in levels of habitual physical activity and thus it is possible
that AD-related behavioral changes may exacerbate age-related bone loss. Habitual physical
activity level, however, was not associated with BMD and controlling for physical activity did
not modify AD-related BMD differences or the relationship between BMD and brain volume.
Smoking is another major lifestyle risk factor for osteoporosis and appears to have negative
effects on bone mass at the major sites of osteoporotic fractures (Egger, Duggleby et al. 1996;
Papaioannou, Kennedy et al. 2009). In our cohort, however, whole body BMD was not
associated with smoking and controlling for smoking did not attenuate the relationship between
brain atrophy and BMD in AD. We examined additional factors that may influence bone mass
such as physical frailty (Kenny, Waynik et al. 2006; Buchman, Boyle et al. 2007), depressive
signs (Diem, Blackwell et al. 2007; Wilson, Arnold et al. 2008), and hormone-replacement
therapy including vitamin D and calcium supplement intake and we found no evidence that they
influenced bone loss in the early stages of AD.
Another possible explanation of the current results is that AD-related
neurodegenerative brain changes may directly affect central control of bone remodeling. Atrophy
of the limbic system, including the hypothalamus, is prominent in AD (Callen, Black et al.
2001). The hypothalamus is a central regulator of a number of homeostatic metabolic processes
including a major role in regulating bone mass (Zaidi 2007). Our results demonstrate the
independent association of BMD with whole brain volume in early AD and suggest that
neurodegenerative changes may influence bone mass in AD. Future studies should assess
regional brain atrophy, including the limbic system, to examine the hypothesis that
neurodegeneration may contribute to loss of bone mass in AD.
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Limitations of the study include the cross-sectional design that reduces our ability to
infer causal relationships among variables. Further longitudinal and interventional studies are
necessary to establish cause and effect. Additionally, the sample size limits the power to fully
examine the influence of covariates on BMD. We did not examine peripheral factors related to
bone health including estrogen, calcium, and vitamin D serum levels, all of which have been
linked to AD although we did take into account participant use of such therapies. Given that our
study participants are a convenience sample, it remains possible that our results may be
influenced by sampling bias. Additionally, our AD sample was confined to the earliest clinical
stages of AD, with most of the demented subjects (80.3%) were in the very mild (CDR 0.5)
stage, comparable to mild cognitive impairment. Although this very early AD group is one of the
strengths of the study, it limits the range of dementia severity and may have reduced our power
to resolve a relationship between BMD and dementia severity and other variables. Nevertheless,
to our knowledge, this is the first study to suggest that bone loss is apparent in men and women
in the earliest clinical stages of AD and that bone mineral density is related to brain structure and
cognitive performance.
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Table 2. 1 Sample characteristics
Non-demented
(n=69)
Early AD
(n=71)
p-value
Age (years) 73.3 (6.9) 74.9 (6.6) 0.173
Education (years) 16.5 (2.7) 15.3 (3.4) 0.015
Females, n (% ) 40 (58) 41 (57.7) 0.94
Bone mineral density (g/cm²) 1.156 (0.12) 1.112 (0.13) 0.02
Whole brain volume (% ICV) 78.0 (2.8) 75.3 (3.3) <0.001
BMI (kg/m²) 25.7 (3.6) 25.0 (5.1) 0.24
Body fat (%) 36.7 (9.0) 36.6 (9.9) 0.95
Serum cholesterol (mg/dL) 182.8 (34.3) 188.7 (37.4) 0.33
Serum triglycerides(mg/dL) 111.3 (53.4) 120.1 (61.5) 0.37
HDL(mg/dL) 55.0 (13.1) 54.0 (13.4) 0.69
LDL(mg/dL) 105.5 (25.7) 111.6 (30.2) 0.21
MMSE 29.4 (0.8) 26.1 (3.5) <0.001
ApoE4 carriers, n(% ) 19 (27.9) 39 (58.2) <0.001
Geriatric Depression Scale 0.83 (0.95) 1.72 (1.57) <0.001
Physical activity (PASE) 125.27 (63.6) 98.00 (56.3) <0.001
Frailty (PPT) 30.45 (3.4) 27.59 (3.8) <0.001
All data represent means (SD), unless otherwise noted. AD- Alzheimer’s disease; % ICV-
represents percent of intracranial volume; BMI- body mass index; HDL- high-density
lipoproteins; LDL- low-density lipoproteins; MMSE- Mini-Mental State Examination; ApoE4-
Apolipoprotein E; PASE- Physical Activity Scale for the Elderly; PPT- Physical Performance
Test
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Table 2. 2 Current medications
Medications Non-demented
(n=69)
Early AD
(n=71)
p-value
Beta-blockers, n (%) 3 (4.3%) 9 (12.7%) 0.08
Thyroid hormone replacement, n (%) 12 (17.4%) 9 (12.9%) 0.44
Hormone replacement therapy, n (%) 9 (13%) 7 (9.9%) 0.55
Bisphosphonates, n (%) 12 (17.4%) 14 (19.7%) 0.72
Vitamin D, n (%) 29 (42%) 19 (26.8%) 0.06
Calcium, n (%) 34 (49.3%) 28 (39.4%) 0.16
All data represent number (%) of participants in each group. AD- Alzheimer’s disease
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Bone mineral density (BMD, in g/cm2) is reduced in males and females in the early stages of
Alzheimer’s disease (AD). Grey bars – non-demented group, white bars- early AD.
Figure 2. 1 Bone mineral density in non-demented and early AD groups
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Relationship between whole brain volume and whole body bone mineral density in the non-
demented (dotted line) and early AD groups (solid line).
Larger normalized whole brain volumes (less brain atrophy) are associated with higher whole
body bone mineral density. Open circles represent non-demented participants (CDR 0) and filled
circles represent participants with early stages of AD (CDR 0.5 and 1). Normalized whole brain
volume is in % of total intracranial volume.
Figure 2. 2 Relationship between whole brain volume and whole body bone mineral density in
the non-demented and early AD groups
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Chapter 3 Preface
In Chapter 2, we demonstrated that BMD was reduced in the earliest clinical stages of AD
in both men and women. Additionally, BMD was related to whole brain volume and cognitive
performance in AD, with higher BMD associated with higher whole brain volume (less brain
atrophy) and better cognitive performance. These results suggest that AD-related brain changes
may affect bone remodeling or that bone loss and AD may share common biological
mechanisms.
As discussed in Chapter 1, recent evidence allowed us to hypothesize that AD related
structural changes in the hypothalamus may be one of the mechanisms of accelerated bone loss
in AD. However, there have been no studies to investigate whether neurodegeneration of CNS
and the hypothalamus specifically, is associated with bone loss.
In Chapter 3, we present a cross-sectional study examining the relationship of BMD with
regional grey matter volume (as opposed to whole brain volume), including the hypothalamus, in
a sample of participants with early AD and non-demented controls.
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Chapter 3
Reduced limbic and hypothalamic volumes correlate with bone density in early
Alzheimer's disease
Loskutova N, Honea R, Vidoni E, Brooks W, Burns J, 2010, Journal of Alzheimer’s Disease
20(1):313-22
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3.1 ABSTRACT
Accelerated bone loss is associated with Alzheimer’s disease (AD). Although the central nervous
system (CNS) plays a direct role in regulating bone mass, primarily through the actions of the
hypothalamus, there is little work investigating the possible role of neurodegeneration in bone
loss. In this cross-sectional study, we examined the association between bone mineral density
(BMD) and neuroimaging markers of neurodegeneration (i.e. global and regional measures of
brain volume) in early AD and non-demented aging. Fifty-five non-demented and 63 early AD
participants underwent standard neurological and neuropsychological assessment, structural MRI
scanning and dual energy x-ray absorptiometry. In early AD, voxel-based morphometry (VBM)
analyses demonstrated that low BMD was associated with low volume in limbic grey natter
(GM) including the hypothalamus, cingulate, and parahippocampal gyri and in the left superior
temporal gyrus and left inferior parietal cortex. No relationship between BMD and regional GM
volume was found in non-demented controls. The hypothesis-driven region of interest analysis
further isolating the hypothalamus demonstrated a positive relationship between BMD and
hypothalamic volume after controlling for age and gender in the early AD group but not in non-
demented controls. These results demonstrate that lower BMD is associated with lower
hypothalamic volume in early AD, suggesting that central mechanisms of bone remodeling may
be disrupted by neurodegeneration.
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3.2 INTRODUCTION
Epidemiologic projections indicate that the incidence of Alzheimer’s disease (AD) will
increase dramatically in the coming decades due largely to the demographics of the disease and
our aging population. Associated cognitive and physical decline greatly contributes to disability
in older adults and places considerable burden on the health system, patients, and caregivers.
Bone health is an important issue in AD given that AD patients are at higher risk than
cognitively healthy adults for osteoporosis, falls, bone fractures and poor post-fracture outcomes
(Buchner and Larson 1987; Weller 2000). Bone mineral density is a strong predictor of bone
fractures and accounts for 60-70% of bone strength (Ammann and Rizzoli 2003). We have
previously demonstrated that BMD is reduced in both men and women in the earliest clinical
stages of AD compared to non-demented older adults independent of habitual physical activity,
smoking, depression, estrogen replacement, and apolipoprotein E4 carrier status. Moreover, low
BMD was independently associated with lower whole brain volume and memory deficits,
suggesting that degeneration of the central nervous system (CNS) may play a role in bone loss
(Loskutova, Honea et al. 2009). However, it is unknown whether bone loss is related to volume
loss in specific regions of the brain, such as the hypothalamus.
Bone mass is maintained locally by the balance between bone resorption by osteoclasts
and bone formation by osteoblasts. Multiple factors modulate this servo system and perturbations
of this system can result in bone loss. The most important and well-studied regulators of bone
health are calcium and vitamin D availability, sex steroids, and mechanical usage. Recent work,
however, indicates that the CNS directly regulates bone remodeling through the actions of the
hypothalamus through two distinct pathways, the neurohumoral and neural arms (Harada and
Rodan 2003; Takeda 2005). Briefly, the neurohumoral arm involves hypothalamic control of the
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anterior pituitary hormones, such as growth hormone (GH), thyroid stimulating hormone (TSH)
and follicle-stimulating hormone (FSH) (see (Zaidi 2007) for a full review). GH executes its
anabolic action on bone through insulin-like growth factor 1 (IGF-1). TSH and FSH receptors
are present in bone cells and receptor activation stimulates bone resorption. The neural arm
involves hypothalamic control of bone remodeling through sympathetic nervous system (SNS)
output. SNS output from the leptinergic/peptidergic neurons in the ventral hypothalamus directly
regulates bone remodeling through activation of beta-2 adreno-receptors on the osteoblasts,
resulting in reduced bone formation (Takeda and Karsenty 2008). There is evidence that
sympathetic output from the hypothalamus via the neural arm may be more important than
actions of sex steroids in the regulation of bone remodeling (Elefteriou, Takeda et al. 2004;
Pogoda, Egermann et al. 2006).
Clinical, neuropathological, and neuroimaging data together suggest that the
hypothalamus is affected in AD and undergoes neuronal loss (de Lacalle, Iraizoz et al. 1993),
profound plaque and tangle formation (Saper and German 1987; Standaert, Lee et al. 1991) and
overall atrophy (Callen, Black et al. 2001). However, there have been no studies to investigate
whether neurodegeneration of CNS, and the hypothalamus specifically, is associated with bone
loss. We hypothesized that atrophy of the hypothalamus and loss of hypothalamic neurons
associated with AD may be one of the mechanisms of accelerated bone loss in AD. Thus, the aim
of this cross-sectional study was to examine the underlying neural substrate of an association
between BMD and brain volume and establish specific correlations of regional grey matter (GM)
with bone loss in early AD and non-demented aging using voxel-based morphometry (VBM)
analysis.
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3. 3 MATERIALS AND METHODS
Sample and recruitment
71 patients with early-stage AD (Clinical Dementia Rating (CDR) 0.5 (n=57) and CDR 1
(n=14)) and 69 non-demented elderly control participants (CDR 0) were enrolled in the
University of Kansas Brain Aging Project. Of these, 16 non-demented and 6 early AD
participants were excluded for excessive head motion. The final sample included 63 patients with
early-stage AD (Clinical Dementia Rating (CDR) 0.5, (n=49) and CDR 1 (n=14)) and 55 non-
demented elderly control participants (CDR 0). Participants were recruited from a referral based
memory clinic and by media appeals. All participants had standard neurological and
neuropsychological assessment, structural MRI scanning and dual energy x-ray absorptiometry.
Mini-Mental State Examination (MMSE) was administered as a standard measure of global
cognition (Folstein, Folstein et al. 1975). The absence or presence and severity of AD were
determined by a standard clinical evaluation that included the CDR (Morris 1993). Detailed
clinical assessment methodology and clinical and neurological characteristics of the study
participants have been presented previously (Burns, Cronk et al. 2008). Participants with a
history of neurologic disease other than AD, diabetes mellitus, ischemic heart disease,
schizophrenia, major depression, alcohol abuse, contraindications to MRI, and use of
antipsychotic and other investigational medications were excluded from the study. Signed
institutionally approved informed consent was obtained prior to enrollment from all participants
or their legal representatives.
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Whole body bone mineral density
Dual energy x-ray absorptiometry (DXA; Prodigy fan-beam densitometer, Lunar Corp.,
GE Medical Systems, Madison, WI) was used to determine total skeleton BMD. We used whole
body BMD, mostly determined by cortical bone (Szulc, Marchand et al. 2000), as a measure of
global bone health that gives a comprehensive view of the whole skeleton(Blake, Herd et al.
2000). Cortical bone porosity and decline in mechanical properties are reported in aging
(McCalden, McGeough et al. 1993) and associated with fractures. Cortical bone density decline
is found to be more specific than trabecular BMD loss for the older population and may play an
important role in bone fragility in elderly (Uusi-Rasi, Sievanen et al. 2007; Seeman 2008).
Magnetic resonance imaging and voxel-based morphometry
Structural MRI data were obtained at the Hoglund Brain Imaging Center with a 3.0 T
Allegra MR scanner (Siemens Medical Solutions, Erlangen, Germany). T1-weighted
magnetization prepared rapid gradient echo (MP-RAGE) sequence (1x1x1mm3 voxels; TR =
2500ms, TE = 4.38ms, TI = 1100ms, FOV 256x256cm2 with 18% oversample, flip angle 8
degrees) were collected and processed for voxel-based morphometry (VBM) analysis. Every
scan was examined for image artifacts and gross anatomical abnormalities. Sixteen non-
demented and six demented subjects were excluded for movement artifact or inhomogeneity that
distorted brain matter. We used MRIcro® software to reconstruct raw Dicom images. Data
analysis for 55 non-demented and 63 AD subjects was performed using the VBM5 toolbox
(http://dbm.neuro.uni-jena.de), an extension of the SPM5 algorithms (Wellcome Department of
Cognitive Neurology, London, UK) running under MATLAB 7.1 (The MathWorks, Natick, MA,
USA) on Linux. The VBM5 toolbox extends and enhances the unified segmentation approach
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implemented in SPM5 (Ashburner and Friston 2005) by using a generative model that integrates
tissue classification, image registration and MRI inhomogeneity bias correction. The approach
allows for more accurate classification of brain tissues in presence of excess atrophy or abnormal
morphology (Meisenzahl, Koutsouleris et al. 2008; Wilke, Holland et al. 2008). Images were
then modulated and saved using affine registration plus non-linear spatial normalization (Wilke,
Holland et al. 2008), resulting in final tissue maps of grey matter (GM), white matter (WM) and
cerebro-spinal fluid (CSF) and smoothed with a 10 mm FWHM Gaussian kernel before
statistical analysis. Additionally, for each study participant total GM, WM, CSF and whole brain
volumes (GM plus WM) in cm3 were computed using the normalized tissue maps of each study
participant. Finally, total hypothalamic volumes in cm3 were derived from small volume
correction (SVC) analysis in VBM.
Statistical analyses
Statistical analyses were conducted using SPSS (Version 16, SPSS Inc., Chicago, Ill).
Continuous variables were summarized as means ± standard deviation (SD) and categorical
variables were summarized by percent. Independent samples t-tests were used for analyzing
group differences in continuous variables and chi-square statistics were used for categorical data.
Effect size for total hypothalamic volume was computed using G*Power3 free software (Faul,
Erdfelder et al. 2007). Partial correlations controlling for age and gender were used to examine
an association between BMD, CDR score, MMSE and brain volumes. Statistical significance
was tested at a=0.05.
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Imaging Statistics
To analyze brain images in SPM5, we used a linear regression model with independence
between subject groups, unequal variance, no grand mean scaling, and centered covariates on the
overall mean. We used absolute threshold masking set at 0.10 to restrict each analysis to one
tissue type. First, the relationship of BMD to brain volume was assessed across all voxels within
each group using multiple regression analysis, with age and gender as confounding variables.
The relationship between BMD and regional GM was considered significant at p<0.001
uncorrected. We then examined the relationship of BMD with hypothalamic volumes using the
small volume corrections (SVCs). The bilateral hypothalami were derived from the Wake Forest
University Pickatlas (http://www.fmri.wfubmc.edu) (Maldjian, Laurienti et al. 2003). These
hypothalamic volumes of interest (VOIs) were pre-selected based on our hypothesis that the
hypothalamic control of bone remodeling is affected in AD(Zaidi 2007). To correct for multiple
comparisons in SVC analyses, results were considered significant at p<0.05 FWE. The
hypothalamic volumes were extracted for each participant from the previous automated step and
used for visualization purposes in graphic representations and secondary correlation analyses
within AD group. All analyses were covaried for age and gender. The x, y, z coordinates of the
areas of significant correlation were obtained from the analyses and reported with reference to
the Montreal Neurological Institute (MNI) standard space within SPM5 after conversion to the
standard space of Talaraich and Tournoux using custom software (Honea, Meyer-Lindenberg et
al. 2008).
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3.4 RESULTS
Sample description
Demographic and clinical characteristics of the participants in the non-demented (n=55)
and early AD groups (n=63) are summarized in Table 1. Early AD and non-demented groups
were similar in age (mean age 73.9±6.4 years) and gender distribution. As expected, participants
with AD had mild deficits in global cognition (MMSE 26.1±3.7 vs. 29.5± 0.7 in non-demented,
p<0.001). The groups did not differ in the use of anti-osteoporotic medications and vitamin D
and calcium supplements as has been reported in details previously (Loskutova, Honea et al.
2009).
As we previously reported in a larger group of these participants (Loskutova, Honea et al.
2009), mean whole body BMD was lower in the early AD group (1.11 ± 0.13) compared to the
non-demented control group (1.16 ± 0.12, p=0.03). As expected, BMD decreased with age (r=-
0.22, p=0.02) and was lower in females (1.08± 0.10) than in males (1.21± 0.12, p<0.001). The
early AD group had smaller mean normalized whole brain (p<0.001) and grey matter volumes (p
<0.001) than the non-demented group. White matter volumes did not differ between groups
(p=0.42).
Bone density and brain structure
We first assessed the relationship of BMD with regional brain volumes on a global level
(across the entire grey matter) followed by SVC analyses confined to the hypothalamus using
VBM neuroimaging analyses. Given the group differences in brain volume and BMD, we
assessed the non-demented and early AD groups separately to avoid correlations driven by these
group differences. All analyses were controlled for age and gender.
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In the early AD group, analysis of regional GM volume adjusted for age and gender
showed that BMD was significantly associated with large clusters of GM areas in the left
superior temporal gyrus and left inferior parietal cortex, with the peak voxels in the left inferior
parietal lobule (BA 40), and in the limbic GM with peaks in the cingulate, parahippocampal gyri,
and the hypothalamus (Figure 1). All clusters for the voxel-wise analyses (k>100, Z>3.4 and p
uncorrected <0.001) are presented in Table 2. There were no significant inverse correlations
between BMD and regional GM volumes. We did not observe any significant relationship
between BMD and GM volume of any area in the non-demented group.
Bone density and hypothalamic volume
We specifically tested the hypothesis that hypothalamic volume was associated with
BMD. The hypothesis-driven SVC isolating the hypothalamus demonstrated a significant
positive relationship between BMD and the hypothalamus after controlling for age and gender in
the early AD group (Figure 2). The significant cluster for each result was extracted using the
VOI function in SPM5 and the mean volume per cluster for each individual was used to plot the
results for visualization purposes.
Secondary analyses of the hypothalamic volumes derived for each individual
demonstrated a difference between groups (p<0.001, effect size d=0.61) with lower volumes in
AD (0.57cm³ ± 0.10) compared to non-demented controls (0.65 cm³ ± 0.12). We did not observe
any relationship between BMD and hypothalamic volume in the non-demented group (r=0.15;
p=0.3; Figure 3). Total hypothalamic volume was associated with BMD (r=0.34, p=0.007) in
AD. The magnitude of this association was moderate in the CDR 0.5 sub-group (very mild AD;
r=0.33, p=0.03) and larger in the CDR 1 sub-group (mild AD; r= 0.59, p=0.04) of AD patients
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(Figure 4). There was, however, not a significant CDR * hypothalamic volume interaction
(p=0.38) for AD participants perhaps related to the small CDR 1 sample size (n=14).
3.5 DISCUSSION
In our previous work, we demonstrated a relationship between bone mineral density and
lower whole brain volume in the earliest clinical stages of AD and proposed a hypothesis that
neurodegenerative changes may influence bone mass in AD via alteration in the central
regulatory mechanism of bone remodeling controlled by the hypothalamus (Loskutova, Honea et
al. 2009). This study extends the prior study by identifying specific regional relationships
between BMD and grey matter volume, including the hypothalamus, that are present in early AD
but not non-demented controls.
Our data suggest that hypothalamic volume is reduced in individuals in the early clinical
stages of AD compared to non-demented older adults, consistent with prior studies
demonstrating lower hypothalamic volume in AD (Callen, Black et al. 2001). Furthermore, by
using VBM neuroimaging analyses we have demonstrated that hypothalamic volume is
associated with whole body BMD, with lower hypothalamic volumes correlated with reduced
BMD in the AD group. Additionally, we have demonstrated that lower grey matter volume in
other areas predominantly affected in AD correlates with BMD reductions. These data suggest
that AD-related neurodegeneration, in particular affecting the hypothalamus, may disrupt central
mechanisms regulating bone mass and contribute to bone loss in early AD.
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Brain atrophy in AD
The hypothalamus, a part of the limbic system, has extensive connections within the
brain and modulates a variety of regulatory processes including appetite, energy expenditure,
sleep and wakefulness and stress responses, all of which are disturbed in AD (Chouinard,
Lavigne et al. 1998; Volicer, Harper et al. 2001). Additionally, the hypothalamus plays a role in
memory through connections with the hippocampal formation. Brain atrophy, a sensitive marker
of neurodegeneration, progresses in a relatively stereotypical fashion through the course of AD,
beginning in the limbic system (i.e., the posterior cingulate and the hippocampus), progressing to
the temporal-parietal cortices followed by the frontal lobes and late in the disease the occipital
lobe and sensorimotor cortices (Thompson, Hayashi et al. 2007). Evidence of AD-related limbic
atrophy in the hypothalamus is limited but has been reported using manual tracing of the
structure (Callen, Black et al. 2001). We used automated VBM-based volume computation to
assess hypothalamic volume and found evidence of hypothalamic volume loss in AD with a
similar effect size as that previously reported. Thus, although our hypothalamic volumes were
slightly larger than the previous manual tracing studies (Callen, Black et al. 2001), our results
using automated estimation of the hypothalamic volume corroborate previously reported findings
of smaller hypothalami in AD, suggesting that atrophy is present in the hypothalamus in AD.
Bone density and brain structure
Our results demonstrate that BMD is associated with hypothalamic volume in AD, with
smaller hypothalamic volumes associated with lower BMD independent of age and gender. This
relationship was observed in AD participants only and not in non-demented controls, suggesting
the relationship of BMD with hypothalamic volume may be AD-specific. Our findings of
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associations between BMD and lower GM volumes of the parietal and temporal cortices and
limbic system, areas of the brain that are preferentially affected in the early stages of the disease
(Honea et al., ADAD, 2009 in press), further suggests this relationship is specific to AD. These
findings extend prior observations associating BMD with cognitive decline (Lui, Stone et al.
2003) and an increased risk of AD (Yaffe, Browner et al. 1999; Tan, Seshadri et al. 2005). We
interpret these findings as suggesting either the presence of a pathological mechanism common
to both bone loss and limbic atrophy or that hypothalamic atrophy in AD may contribute to bone
loss via alterations in central regulatory mechanisms of bone remodeling.
Pathological changes occur in the hypothalamus in AD and include profound neuronal
loss (de Lacalle, Iraizoz et al. 1993), abundant AD plaques and tau tangles (Standaert, Lee et al.
1991) and overall volume loss (Callen, Black et al. 2001). AD is associated with clinical
symptoms referable to hypothalamic dysfunction including sleep and circadian rhythm
disturbances (Wu and Swaab 2005), alterations in appetite and energy expenditure, and body
wasting (Deshmukh and Deshmukh 1990; Ferrari, Arcaini et al. 2000). Thus, it is plausible that
hypothalamic damage could result in clinically evident bone loss, given the central role the
hypothalamus plays in regulating bone mass. The hypothalamus regulates bone mass through
both a direct neural pathway and through the neurohumoral arm (Takeda 2005). Although, this
study does not assess direct measures of hypothalamic dysfunction, there is abundant evidence of
AD-related dysfunction in both the neurohumoral and neural arms. Dysfunction of the
hypothalamo-pituitary axis and activity of the SNS are reported in AD. For instance, GH levels
(Gomez 2008) are reduced in AD while interestingly a number of other hypothalamic factors are
increased in AD, including corticotropin-releasing hormone (CRH) (Raadsheer, van Heerikhuize
et al. 1995), cortisol (Rasmuson, Andrew et al. 2001); (Peskind, Wilkinson et al. 2001), FSH
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(Bowen, Isley et al. 2000; Meethal, Smith et al. 2005), and TSH (de Jong, Masaki et al. 2007).
Additionally, several studies demonstrate evidence of increased sympathetic activity (Pascualy,
Petrie et al. 2000) including increased brain noradrenergic activity and elevated serum and
cerebrospinal fluid levels of norepinephrine (Raskind, Peskind et al. 1984; Elrod, Peskind et al.
1997; Raskind, Peskind et al. 1999). Why increased activity has been observed in some aspects
of the hypothalamic-pituitary axis in AD remains unclear but may be related to disturbed
negative feedback (Elgh, Lindqvist Astot et al. 2006) while increased SNS activity may be
related to overcompensation of remaining noradrenergic neurons in response to profound
noradrenergic neuronal loss (Szot, Leverenz et al. 2000). Thus, further study should examine if
hypothalamic structural change in AD alters neurohumoral systemic mediators of bone
remodeling such as the pro-resorption factors (cortisol, FSH, and TSH, and sympathetic output)
and bone formation factors (GH).
Additionally, common factors, such as vitamin D deficiency, have been linked to both
AD (Oudshoorn, Mattace-Raso et al. 2008; Annweiler, Allali et al. 2009; Masoumi, Goldenson
et al. 2009) and bone loss (Holick 2006; Holick 2007; Holick 2007). Recent discovery of vitamin
D receptors in rodent(Jirikowski, Kauntzer et al. 2009) and human hypothalamus (Eyles, Smith
et al. 2005) indicates that vitamin D may affect hypothalamic function or serve as central
neuroactive substance. The possibility that vitamin D deficiency contributes to AD pathology,
hypothalamic dysfunction and subsequent bone loss should be explored in the future studies.
It is important to recognize that the cross-sectional design of the study limits our ability
to examine temporal development and cause-effect relationship between BMD and regional
brain volumes. Additionally, the role of AD severity in this relationship should be more precisely
defined in future studies. In addition, given that our study participants are a convenience sample,
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it remains possible that our results may be influenced by sampling bias. Our data suggest that the
association between BMD and total hypothalamic volume may be accentuated in more advanced
AD, with a larger relationship observed in more advanced AD (CDR 1 vs. CDR 0.5). Although,
our very early AD group is one of the strengths of the study, the relatively narrow range of
dementia severity limits our ability to examine bone loss - regional brain volume relationship in
more advanced stages of AD.
In conclusion, to our knowledge, this is the first study to demonstrate that lower BMD is
associated with lower hypothalamic volume in early AD, suggesting that central mechanisms
may contribute to AD-related bone loss. Bone loss in AD is an increasingly important clinical
problem that may thus require different treatment approaches and preventive strategies as central
mechanisms of bone remodeling may be disrupted by neurodegeneration.
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Table 3. 1 Sample characteristics
ND n=55 AD n=63 p-value
Age (years) 73.2 (6.3) 74.4 (6.5) 0.30
Females (n) 32 39 0.68
MMSE 29.5 (0.7) 26.1 (3.7) <0.001
BMD (g/cm²) 1.16 (0.12) 1.11 (0.13) 0.03
WBV (cm³) 945.6 (87.2) 861.4 (93.6) <0.001
GMV (% of ICV) 43.0 (2.1) 40. 7 (2.4) <0.001
WMV (% of ICV) 34.8 (1.8) 34.5 (2.3) 0.42
Total Hypothalamic
volume (cm³)
0.65 (0.12) 0.57 (0.10) <0.001
MMSE- Mini-Mental State Examination ; BMD- whole body bone mineral density; WBV-
normalized whole brain volume in cm³; ICV- total intracranial volume; GMD-grey matter
volume; WMV- white matter volume.
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Table 3. 2 Positive correlations between BMD and grey matter volume in the participants with
AD with adjustment for age and gender
Only clusters for the voxel-wise analysis with k>100, Z>3.4 and p uncorrected <0.001
uncorrected are listed; K-cluster size; L-left; R- right; BA-Brodmann area; MNI- Montreal
Neurological Institute; FWE- Family-Wise Error; uncor-uncorrected p value.
Z
x y z FWE uncor
Parietal L Inferior Parietal
lobule, BA,40
-60 -47 22 0.03 <.001
2 3750 Limbic L Precuneus
Posterior
Cingulate, BA23
-5 -57 12 4 0.42 <.001
Subcortical Hypothalamus -1 3 -15 4.11 0.3 <.001
4 1509 Limbic R Cingulate Gyrus 2 -1 42 3.54 0.9 <.001
Limbic L Cingulate Gyrus,
BA 32
-5 6 43 3.49 0.93 <.001
Frontal R Medial Frontal
Gyrus, BA 9
8 27 34 3.48 0.94 <.001
5 390 Occipital L Middle occipital
gyrus
-49 -69 -15 3.45 0.95 <.001
Anatomical
Region
K
C
lu
st
er
Temporal L Superior
temporal gyrus
-43
-13 3.43 0.96 <.001R
Parahippocampal/
Fusiform
Talairach Region
11 -15 0.11 <.001
1 -20 4.31 0.16 <.001
6 143 Limbic 22 -44
Talairach coordinates in
MNI space P Value
1 17864 4.74
3 2222 Limbic L
Parahippocampal
Gyrus, BA 34
-12
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Areas in yellow indicate regions where grey matter volume correlates with bone mineral density
in AD participants. Identified regions include the left superior temporal gyrus, left inferior
parietal cortex (peak voxels in the left inferior parietal lobule [BA 40]), and limbic GM (peaks in
the cingulate, parahippocampal gyri, and the hypothalamus). Analyses were controlled for age
and sex and reported as significant at p<0.001 uncorrected (see Table 2). The coronal image is
presented in neurological orientation (left is left).
Figure 3. 1 Whole brain VBM results in AD
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Small volume correction analyses confined to the hypothalamus demonstrate a significant
positive correlation between whole body bone mineral density and the hypothalamic volume
after controlling for age and sex (p<0.05 FWE) in the early AD group. The coronal image is
presented in neurological orientation (left is left).
Figure 3. 2 Hypothalamic volume correlates with BMD in AD
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Figure 3. 3 Hypothalamic volume and BMD in non-demented
Insignificant relationship between whole body bone mineral density and total volume of the
hypothalamus (b0=0.79, b1=-1.2, p=0.3) in non-demented group.
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Figure 3. 4 Hypothalamic volume and BMD in AD
Positive relationship between whole body bone mineral density and total volume of the
hypothalamus (b0=-1.93, b1=3.4, p=0.007) in the early AD group (clinical dementia rating
(CDR) 0.5 (filled circles) and CDR 1.0 (open circles).
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Chapter 4 Preface
In Chapter 3 we demonstrated, by using voxel-based morphometry (VBM) automated
neuroimaging analysis that hypothalamic volume was associated with whole body BMD, and
lower hypothalamic volumes correlated with reduced BMD in the AD group. VBM is a powerful
technique for systematic evaluation of the whole brain and statistical analysis. This method has
gained substantial popularity in neuroimaging studies.
Generally in the neuroimaging field, manual volumetry, or manual tracing of a brain
structure by a trained human operator, is regarded as a “gold standard” while automated methods
are often referred to as a “black box”. There is legitimate concern particularly in regards to face,
or anatomical, validity of automated methods. Given that VBM also allows measuring volumes
of different brain regions including the hypothalamus we were interested in testing and
comparing its performance with “gold standard” manual volumetry of the hypothalamus in
application to AD research. Chapter 4 presents the results of a cross-sectional study that was
designed to provide guidance for method selection in future neuroimaging studies of the
hypothalamus.
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Chapter 4
Cross-sectional estimation of the hypothalamic volume by atlas-based VBM compared to
manual tracing in application to Alzheimer’s disease
Loskutova N, Honea R, Brooks W, Burns J (to be submitted to NeuroImage, 2011).
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4.1 ABSTRACT
The hypothalamus is a key brain structure that modulates a variety of neuroendocrine and
regulatory processes including appetite, energy expenditure, sleep, wakefulness, stress responses
and mood and memory, all of which are disturbed in Alzheimer’s disease (AD). Clinical and
pathologic evidence suggests that the hypothalamus might be affected by AD, however few
studies used neuroimaging to assess anatomical changes in the hypothalamus. In this study, we
compared the hypothalamic volumes estimated by voxel-based morphometry (VBM) and manual
volumetry for 19 participants with early AD and 19 non-demented controls. Manual tracing was
performed on unmanipulated T1-weighted images (intra-rater ICC for the hypothalamus was
0.89). The correlation between manual (adjusted for the head size) and atlas-based VBM
volumetry total hypothalamic volumes was r= 0.57 p<0.001. Atlas-based VBM hypothalamic
volumes were larger than manual volumes (614.0±104.0 vs. 333.4±49.9 mm3). Total
hypothalamic volume was larger in nondemented vs. AD when using atlas based VBM methods
(p<0.001), but no group differences were observed with manual tracing (p=0.42). Clinical
measures of memory and cognitive performance correlated with hypothalamic volumes extracted
by atlas-based VBM but not with manual volumetry results. Atlas-based VBM shows promise
as a useful tool for regional volumetry of the hypothalamus, as it correlated with clinical
measures, detected group differences and had fair agreement with manual tracing of the
hypothalamus in a cross-sectional study.
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4.2 INTRODUCTION
Alzheimer’s disease (AD), the most common cause of dementia, is associated with
pathological and functional changes in the hypothalamus (Saper and German 1987; Standaert,
Lee et al. 1991; Chouinard, Lavigne et al. 1998; Pascualy, Petrie et al. 2000; Volicer, Harper et
al. 2001). The hypothalamus, the ventral-most part of the diencephalon, contains at least 12
defined nuclei and has extensive connections within the brain. The hypothalamus regulates a
variety of neuroendocrine, autonomic and somatic functions and is involved in memory and
mood processing. Senescence and AD-related decline are associated with dysregulation and
decline in hypothalamic function with subsequent decline in pituitary, gonadal and adrenal
functions, however, cause – effect relationship between hypothalamic dysfunction and AD
remains unclear (Gil-Bea, Aisa et al. ; Atwood, Meethal et al. 2005).
Aging is associated with decline in the somatotropic axis and mild partial growth
hormone (GH) deficiency (Giordano, Lanfranco et al. 2005). In AD, profound pathological
changes such as neuronal loss and plaque and tangle formation are reported in most of the
hypothalamic nuclei (Swaab, Goudsmit et al. 1992). Clinical symptoms of hypothalamic
dysfunction and alterations in hypothalamic-pituitary axis have been consistently reported.
Stimulation of GH release by hypothalamic GH- releasing hormone and GH-secretagogues has
been suggested as a way to delay frailty in older adults (Giordano, Bonelli et al. 2008; Hersch
and Merriam 2008). Development of future AD treatments targets neurohormones and peptides,
such as leptin, GH, GH secretagogues, and insulin-like growth factor I, that either act through the
central hypothalamic mechanisms or are regulated by the hypothalamic and pituitary hormones
(Carro and Torres-Aleman 2004; Vitiello, Moe et al. 2006; Gomez 2008; Signore, Zhang et al.
2008; Tezapsidis, Johnston et al. 2009). There is increasing interest in hypothalamic
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neuroendocrine axis in aging and AD, although it remains unclear whether anatomical changes in
the hypothalamus such as AD related atrophy underlie hypothalamic dysfunction.
High-resolution magnetic resonance imaging (MRI) allows an in vivo assessment of
structural brain changes. MRI has the potential to capture structural changes in the
hypothalamus. However, very few studies have used neuroimaging to assess anatomical changes
in the hypothalamus in AD (Loskutova, Honea et al. ; Callen, Black et al. 2001; Copenhaver,
Rabin et al. 2006). Hypothalamic imaging studies may be more difficult due to challenges in
subcortical segmentation (classification of brain regions) (Fischl, Salat et al. 2002). Manual,
semi-automated and fully automated approaches have been used in segmentation and volumetry
of subcortical grey matter. Manual volumetry is still the most widely used method of
hypothalamic volume estimation, although the well-recognized shortcomings of the method are
numerous. Publically available automated methods (FIRS/FSL, FreeSurfer) developed for
subcortical segmentation are limited in the number or regions that can be studied and do not
separate the hypothalamus from the larger ventral diencephalon region of interest (ROI). Others
(for example, Classifier Fusion and Labeling (CFL) or Profile Active Appearance Model
(AAM)) are not freely available and require substantial technical and computational resources
and expertise. Finally, automated methods, although highly reliable, are often questioned in
regards to their face, or anatomical, validity. Concisely, there is little guidance in the literature
for those interested in using neuroimaging for studying the hypothalamus and hypothalamic
dysfunction in AD.
Voxel-based morphometry (VBM) has gained substantial popularity due to its unique
quality of utilizing digital information available for each voxel and transforming it to estimation
of grey and white matter volumes. VBM is a powerful technique for systematic evaluation of the
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whole brain and statistical analysis that also allows measuring volumes of grey and white matter
in semi-automated region-of-interest (ROI) approach. Optimized VBM with Wake Forest
University Pickatlas (WFU) toolbox also automatically generates segmented atlas ROI templates
and summarizes all the voxel values into grey or white matter volumes within each ROI (Good,
Johnsrude et al. 2001). The WFU Pickatlas incorporates a broad range of ROI templates
including hemisphere, lobar, anatomical label, tissue-type and Brodmann area atlases (Maldjian,
Laurienti et al. 2003; Maldjian, Laurienti et al. 2004). Publically available atlas-based VBM
volumetry is suggested to be unbiased, objective, reliable, and comparable to manual tracing
approach within the capabilities of most research groups (Gonoi, Abe et al.). The advantage of
VBM as an automated technique is that it provides perfectly reproducible result on a given data
set. This approach, however, does not require an a priori hypothesis or extensive training and
knowledge of anatomy, and therefore is one of the main concerns. It is believed that small brain
structures are particularly vulnerable to brain distortions introduced by necessary image
manipulations in VBM. Nevertheless, VBM has been widely and successfully used for detecting
volume differences in small areas of the brain affected by AD pathology. Unfortunately, very
few studies have utilized VBM to study the volume, anatomy and function of the hypothalamus
in AD (Whitwell, Petersen et al. 2007; Whitwell, Weigand et al. 2007).
It has been recommended that VBM and manual volumetry should be used in tandem;
with VBM used as first-pass strategy for hypothesis generation which is followed by manual
volumetry to test a specific hypothesis about certain anatomical regions (Giuliani, Calhoun et al.
2005). We previously demonstrated that VBM detected hypothalamic volume differences
between cognitively normal older controls and participants with early AD (Loskutova, Honea et
al.). The whole brain analysis was followed by the ROI analysis using WFU Pickatlas and small
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volume correction to test a specific hypothesis regarding relationships between hypothalamic
volume and function. The purpose of the present study was to test and compare manual
volumetry of the hypothalamus and ROI analysis using VBM WFU Pick atlas in application to
AD research. Specifically, the goals of the study were:
1. To address the lack of quantitative validation of volumes of the hypothalamus by
comparing atlas-based VBM volumetry with manual volumetry obtained from
unmanipulated images.
2. To assess the application of hypothalamic volumetry with hypothalamic structural changes
in AD and cognitively normal aging.
3. To assess the potential of the VBM WFU Pickatlas for regional volumetry of the
hypothalamus by assessing face, or anatomical, validity of the VBM hypothalamic ROI.
4.3 METHODS
Sample and recruitment
Hypothalamic volumes estimated by atlas-based VBM volumetry were available for 63
participants with early stages of AD (Clinical Dementia Rating, CDR 0.5-1.0) and 55 non-
demented elderly controls (CDR 0) as a part of the University of Kansas Brain Aging Project
(BAP) as previously reported (Loskutova, Honea et al.). The power analysis showed that a total
of 30 participants was sufficient to detect group differences in the hypothalamic volume obtained
by atlas-based VBM volumetry between AD and non-demented aging. To account for possible
exclusions, a random sample of 20 participants with early stages of AD and 20 non-demented
elderly controls (total N=40) was selected from the available BAP pool for the purpose of this
study. All participants had standard neurological and neuropsychological assessment, structural
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MRI scanning and dual energy x-ray absorptiometry. Mini-Mental State Examination (MMSE)
was administered as a standard measure of global cognition (Folstein, Folstein et al. 1975). The
absence or presence and severity of AD were determined by a standard clinical evaluation that
included the CDR and CDR sum of boxes score (Morris 1993). A psychometric battery including
standard tests for memory, executive function and visuospatial ability was administered to every
participant. Scores from all the tests in the psychometric battery were converted to z scores
(higher scores representing better performance) and global cognitive (Global Cognitive index)
and memory performance (Global Memory index) scores were computes as a mean of all z
scores for each participant. Detailed clinical assessment methodology and clinical and
neurological characteristics of the study participants have been presented previously (Burns,
Cronk et al. 2008). Participants with a history of neurologic disease other than AD, diabetes
mellitus, ischemic heart disease, schizophrenia, major depression, alcohol abuse,
contraindications to MRI, and use of antipsychotic and other investigational medications were
excluded from the study. Signed institutionally approved informed consent was obtained prior to
enrollment from all participants or their legal representatives.
Magnetic resonance imaging and voxel-based morphometry
Structural MRI data were obtained at the Hoglund Brain Imaging Center with a 3.0 T
Allegra MR scanner (Siemens Medical Solutions, Erlangen, Germany). T1-weighted
magnetization prepared rapid gradient echo (MP-RAGE) sequence (1x1x1mm3 voxels; TR =
2500ms, TE = 4.38ms, TI = 1100ms, FOV 256x256cm2 with 18% oversample, flip angle 8
degrees) were collected and processed for VBM analysis. Every scan was examined for image
artifacts and gross anatomical abnormalities. We used MRIcro® software to reconstruct raw
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Dicom images. Data analysis was performed using the VBM5 toolbox (http://dbm.neuro.uni-
jena.de), an extension of the SPM5 algorithms (Wellcome Department of Cognitive Neurology,
London, UK) running under MATLAB 7.1 (The MathWorks, Natick, MA, USA) on Linux.
Images were modulated and saved using affine registration plus non-linear spatial normalization
(Wilke, Holland et al. 2008), resulting in final tissue maps of grey matter (GM), white matter
(WM), and cerebrospinal fluid (CSF) and smoothed with a 10 mm FWHM Gaussian kernel.
Additionally, for each study participant, total intracranial volume (TICV), total GM, WM, CSF,
and whole brain volumes (GM plus WM) in cm3 were computed using the normalized tissue
maps of each study participant. Finally, the bilateral hypothalami were derived using ROI
approach and the Wake Forest University Pickatlas toolbox (http://www.fmri.wfubmc.edu)
(Maldjian, Laurienti et al. 2003) from the final grey matter tissue maps of each participant. Total
hypothalamic volumes were computed as a sum of right plus left and reported in mm3. The
detailed procedure for MRI acquisition and VBM processing for the larger group of participants,
40 of whom were randomly selected for the current study, has been previously reported
(Loskutova, Honea et al.).
Manual Tracing protocol
Manual tracing was performed on unmanipulated T1-weighted images using the ITK-
SNAP software (version 1.9.10, www.itksnap.org) (Yushkevich, Piven et al. 2006). Before
tracing, images were checked for alignment to AC-PC plane, rotation and tilt. Images were
initially acquired in aligning to AC-PC plane minimizing the need for re-alignment and
manipulations of the images. Thirty-eight images passed quality control and were included in the
study. Two images were excluded based on midbrain artifacts that distorted the hypothalamus.
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All traces were drawn blind to participants’ group assignment by the same rater (NL). We used
the tracing protocol and procedure manual previously outlined and published by Callen et
al.(Callen, Black et al. 2001) but restricted it to the hypothalamus only. The hypothalamus was
traced on enlarged coronal views with reference to sagittal and axial planes starting where
individual columns of fornices appear (anterior to the mamillary bodies) and ending at the
decussation of the anterior comissure. Medial boundaries were defined by the medial brain
surface. Lateral boundaries were defined as a line connecting superior - lateral edge of the optic
tracts with superior - lateral edge of the fornix. Inferior boundary was defined by the inferior
brain surface and superior boundary was defined as a horizontal line from the medial brain
surface to the bottom of the fornix. Traces included most of the anterior and tuberal regions and a
portion of most anterior-inferior mamillary region and excluded the mamillary bodies and lateral
hypothalamus. Detailed anatomical boundaries and operational instructions of the hypothalamic
tracing protocol can be found elsewhere(Callen, Black et al. 2001). For each image, the total
volume of the hypothalamus was estimated within demarcated area by the ITK-SNAP and
reported in mm3. Intra-rater reliability was assessed after repeated tracing of all selected images
within one week interval by the same rater (NL). The volumetric results of the second tracing
were used for further analyses.
Head size correction
Volumes obtained by the manual tracing were corrected by the total intracranial volume
in order to correct for preexisting differences in head size in further statistical analyses. Total
intracranial volume (TICV) computed by VBM was used for consistency of reference used by
both VBM and manual methods. Average TICV for all participants was 1513.4 cm3 and did not
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differ between early AD and non-demented groups (p=0.82). The correction was made by
dividing participant’s uncorrected hypothalamic volumes obtained from manual volumetry by
the TICV of each participant and multiplying the ratio by the average TICV of the sample. The
group average TICV was selected based on no difference between AD and ND in our sample,
which is consistent with previous findings.
Statistical analyses
Statistical analyses were conducted using SPSS (Version 17, SPSS Inc., Chicago, Ill).
Continuous variables were summarized as means ± standard deviation (SD) and categorical
variables were summarized by ratio. Independent samples t-tests and Mann-Whitney U test were
used for analyzing group differences in continuous variables and chi-square statistics were used
for categorical data. Bland & Altman test was performed using SPSS and custom syntax.
Pearson, Spearman’s rho and partial correlations were used to examine the associations between
hypothalamic volumes of two methods and their associations with demographic and clinical
variables. ANOVA was used to assess gender differences in hypothalamic volumes. Statistical
significance was tested at a=0.05.
Agreement between automated atlas-based VBM and manual methods
The agreement between automated atlas-based VBM volumetry and manual methods was
tested using:
1. Volumes
First, we used Pearson correlation coefficient to assess the strength of a relation between
hypothalamic volumes obtained by atlas-based VBM volumetry and manual volumetry.
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Additionally, we tested the group differences in the hypothalamic volumes estimated by each
method and correlated hypothalamic volumes with demographic and clinical measures in AD
and non-demented aging. We expected to find reduction in hypothalamic volume in AD and that
hypothalamic volumes will correlate with clinical measures of dementia severity. This approach
is widely used in reliability correspondence between methods in neuroimaging (Babalola,
Patenaude et al. 2009).
2. Bland-Altman analysis
Next, we used Bland-Altman analysis to assess whether agreement between two
methods is sufficient (Bland and Altman 1986). Bland-Altman analysis provides information
about whether two measurements are comparable, or interchangeable, without considering either
one as the gold standard. The results of Bland-Altman analysis are summarized in graphic
representation and as the mean difference d, standard deviation of difference s, and the limits of
agreement (d-1.96s and d+1.96s) between hypothalamic volumes obtained by atlas-based VBM
volumetry and manual volumetry. Coefficient of reproducibility for two methods was computed
as CR = 100*SD (diff)/Mean (averages).
Literature search
We performed a PubMed index search using following key words: “hypothalamus”,
“volume” or “volumetry” and “manual”, “VBM” or “voxel-based morphometry”. The search
was restricted to research reports of MRI human studies published in English. The results and
methodology sections of relevant records were assessed for reports of the actual hypothalamic
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volume and the method used. The results of eight articles included in the literature review are
reported in Table 2.
4.4 RESULTS
Sample characteristics:
The final sample included 19 participants with early AD (17 participants with CDR 0.5
and 2 with CDR 1.0, average Sum of Boxes score = 2.95±1.1) and 19 non-demented controls
(CDR 0). The groups did not differ in body composition, education, age and gender distribution.
As expected, early AD group had lower MMSE scores (27.0. ± 3.2) compared to the non-
demented controls (29.4 ± 0.7, p=0.002) and poorer Global Cognitive and Global Memory
performance (Table 1). Whole brain volume was lower in AD (881.5 ± 82.5) compared to non-
demented controls (943.3 ± 93.3, p=0.04) with no difference in the TICV between the groups
(p=0.82).
Intra-rater reliability of manual volumetry:
In the analysis of intra-rater reliability of the tracing protocol, the ICC for the repeated
hypothalamic tracings of all 38 images in the study was 0.89, Spearman-Brown split half
coefficient was 0.90 and coefficient of variation was 8.5%.
Agreement between atlas-based VBM volumetry and manual volumetry
1. Volumes
In the overall group, atlas-based VBM volumetry yielded larger total hypothalamic
volume (614.0±104.0 mm3) than manual volumetry (333.4±49.9 mm3). In the analysis of
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agreement between the methods, the correlation between manual hypothalamic volume and
hypothalamic volume estimated by VBM was r= 0.49, p=0.002. The correlation between total
hypothalamic volumes of two methods improved after adjusting manual results for TICV (r=
0.57 p<0.001) (Figure 1). Correlation between atlas-based VBM and manual tracing was better
in the non-demented r=0.71, p<0.001 than in AD r=0.42, p=0.08.
Bland-Altman Analyses
In the Bland-Altman plot, the mean difference d and standard deviation of difference s
for hypothalamic volumes obtained by atlas-based VBM volumetry and manual volumetry was
277.5 mm3 ± 85.83. The limits of agreement (d-1.96s and d+1.96s) for atlas-based VBM
volumetry and manual volumetry were between 105.8 and 449.15 mm3. The differences fell
within limits of agreement that suggests acceptable degree of agreement between VBM and
manual volumetry in overall sample and within groups. The coefficient of reproducibility for the
two methods was 18.1 %. Atlas-based VBM volumes were systematically larger than volumes
produced by manual tracing. There was a trend towards larger differences between methods for
larger hypothalami and better agreement for smaller volumes (Figure 2).
Group differences and clinical and demographic measures
In the manual tracing protocol, although the absolute volumes of the hypothalamus were
smaller in AD, there was no difference between AD and non-demented groups (340.1 ± 52.5 vs.
326.7±47.7, p=0.42, Table 1). Adjusting for TICV did not change the results (p=0.52). The mean
hypothalamic volumes measured by atlas-based VBM volumetry were smaller in AD than in
non-demented (560.5 ± 69.2 vs. 667.5 ± 106.8, p=0.001).
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The hypothalamic volumes yielded by both methods did not correlate with total brain
volume and age. There was no difference in hypothalamic volumes between men and women for
either method.
The hypothalamic volumes measured by atlas-based VBM volumetry correlated with
Global Cognitive Index (r= 0.39, p=0.02) and Global Memory Index (r= 0.48, p=0.003) and a
trend was observed with MMSE (r= 0.30, p=0.08), after controlling for age and gender. There
was no correlation between total manual hypothalamic volume adjusted for TIVC and any of the
global cognitive measures.
Face validity
Visual inspection showed accurate hypothalamic ROI placement after inspection by a
trained expert for all participants demonstrating good anatomical validity of the automated atlas-
based VBM hypothalamic ROI, as the example in Fig 3 demonstrates.
4.5 DISCUSSION
We examined hypothalamic volumes derived from an atlas-based VBM approach and
manual tracing in a mixed sample of participants with early stages of AD and non-demented
controls. The results of our study demonstrate that the two methods showed an acceptable degree
of agreement, although hypothalamic volumes measured by atlas-based VBM volumetry were
systematically larger by a mean of 277.5 mm3 than manual volumetry. The discrepancy between
the two methods was not affected by the presence of AD, which suggests that these methods
have comparable agreement in neurodegenerative disease and normal aging. In addition, atlas-
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base VBM, but not manual volumetry, was able to detect group differences and correlated with
clinical measures of cognitive performance.
Post-mortem data suggest that the hypothalamus is affected by AD pathology and is a site
of abundant plaque and tangle formation and neuronal loss (Standaert, Lee et al. 1991; Swaab,
Goudsmit et al. 1992). Clinical studies have reported various signs of hypothalamic dysfunction
in patients with AD that may be due to pathological changes in the hypothalamus in AD (Elgh,
Lindqvist Astot et al. 2006). We, therefore, hypothesized that pathological processes may be
manifested as hypothalamic volume loss in AD and can be detected by neuroimaging volumetry.
Atlas-based VBM volumetry detected differences in hypothalamic volume between early AD
and non-demented groups while manual methods did not, suggesting that VBM is more sensitive
to disease-related differences even in a relatively small sample. Numerous previous reports show
that VBM is highly sensitive to brain volume changes in various disease conditions. It is further
supported by the correlations of VBM derived volumes with clinical measures of cognitive and
memory functions in our study. These correlations were not observed using manual volumetry of
the hypothalamus. Our inability to detect hypothalamic differences with manual tracing may be
explained by either insufficient power or that hypothalamic volume loss in AD occurs in
neuronal populations not captured by manual ROI (Swaab, Goudsmit et al. 1992).
Manual volumetric approaches are regarded as a gold standard due to high anatomical or
face validity. In manual volumetry, the MRI image is considered a true analogue of the
neuroanatomy and accurate anatomic volume of a brain structure can be calculated by manual
tracing on the MRI image of the brain in vivo (Bobinski, de Leon et al. 2000). For the automated
methods such as VBM, the main concern in the literature is its questionable face validity.
However, whether questionable face validity refers to possible displacement of an ROI due to
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extensive image manipulations or inability to capture true anatomical volume of the structure
remains unclear. Upon visual inspection of the hypothalamic ROI in the atlas-based VBM the
placement was anatomically correct mostly covering the anterior, tuberal and anterior-most
portion of mammillary regions of the hypothalamus.
According to the postmortem studies, the true volume of the hypothalamus is
approximately 3.6 cm3 (3600mm3), or 0.3-0.5 % of the whole brain volume(Hofman and Swaab
1992). In our study, however, the region of interest in manual tracing was considerably smaller
than the autopsy-defined anatomical volume of the hypothalamus. Since the manual tracing
protocol that we used was limited to the anterior and tuberal regions of the hypothalamus, we
expected somewhat smaller manual volumes. Such dramatic discrepancy with autopsy-defined
hypothalamic volume, however, questions the ability of this method to serve as a gold standard
in volumetric neuroimaging studies of the hypothalamus. Interestingly, most of the published
neuroimaging studies we reviewed to determine the range of the hypothalamic volume used
manual tracing approaches and none resulted in the hypothalamic volumes in its autopsy-defined
anatomical range (Table 2). It is worth noting that numerous in vivo neuroimaging volumetric
studies of the hippocampus have reported hippocampal volumes corresponding to its autopsy-
defined anatomical volume range of 6.0-7.0 cm3 (Walker, Highley et al. 2002) with both, manual
and automated approaches (Geuze, Vermetten et al. 2005; Tae, Kim et al. 2008). Our results
suggest that excellent anatomical validity of manual volumetry cannot be assumed for all brain
structures, unless tested. Although the manual tracing is considered a gold standard in volumetric
studies, a fundamental shortcoming of this method - the discrepancy with autopsy-defined
anatomical volume of the hypothalamus should be addressed before it can be used as a reference
or a gold standard method in future studies. Our results indicate that together with several other
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properties of this approach, such as operator-induced error, time required for individual tracing
of each set of brain slices, lower power in detecting group differences in smaller samples, and
inconsistency of tracing protocols represent methodological limitations in using manual tracing
for studying the hypothalamus in cross-sectional and potentially longitudinal studies.
The VBM approach has some advantages over manual tracing such as absence of
contamination of the results by intra- or inter-rater errors, higher reproducibility of the results
due to use of more standardized ROIs provided by WFU Pickatlas, and greatly reduced
operator’s time required to analyze a certain region. Additionally, the atlas-based VBM
volumetry may have better applications in large-scale research due to higher sensitivity and
power in detecting group differences than the manual tracing of the hypothalamus, and
potentially other small subcortical structures. Results of our study should be interpreted with
caution, however, due to well-recognized sensitivity of VBM to intra- and inter-scanner
variations, difference in scanning protocols and contrast non-uniformity that may affect the GM
probability of deep structures and final volumetric results (Huppertz, Kroll-Seger et al. ; Tardif,
Collins et al.). This issue is especially important in longitudinal studies due to reported
susceptibility of longitudinal VBM to false positives (Thomas, Marrett et al. 2009). Thus,
longitudinal performance of atlas-based VBM of the hypothalamus and other deep structures
needs to be addressed in future studies.
In conclusion, atlas-based VBM showed acceptable degree of agreement with manual
volumetry, demonstrated good anatomical validity and better performance in detecting group
differences and correlations with clinical measures of cognitive performance in a cross-sectional
study. The atlas-based VBM volumetry shows promise as a useful tool for regional volumetry of
the hypothalamus and has advantages over manual tracing as it is currently used.
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Table 4. 1 Sample characteristics
ND (n=19) AD (n=19) P value
Age, (y) 72.9 (6.0) 76.3 (6.2) 0.10
Gender (F/M) 12/7 12/7 1.0
Education (y) 16.5 (2.2) 15.0 (3.4) 0.11
MMSE 29.4 (0.7) 27.0 (3.2) 0.002
Global Cognitive Index (z) 0.04 (0.43) -1.61 (1.16) <0.001
Global Memory Index (z) 0.09 (0.79) -1.82 (1.01) <0.001
Body Mass Index (kg/m2 ) 25.8 (3.7) 25.8 (3.1) 0.98
Gray Matter Volume (VBM), (cm3 ) 501.7 (45.0) 450.4 (48.0) 0.002
Whole Brain Volume (VBM), (cm3 ) 943.3 (93.3) 881.5 (82.5) 0.04
Hypothalamic Volume (VBM), (mm3 ) 667.5 (106.8) 560.5 (69.2) 0.001
Hypothalamic Volume (Manual), (mm3 ) 340.1 (52.5) 326.7(47.7) 0.42
Hypothalamic Volume (Manual normalized,
mm3 )
343.3 (69.2) 329.10 (58.1) 0.52
Total Intracranial Volume (cm3 ) 1520.5 (171.3) 1508.5 (150.3) 0.82
All data represent means (SD), unless otherwise noted. ND- non-demented controls, AD-
Alzheimer’s disease; MMSE- Mini-Mental State Examination; VBM – voxel-based
morphometry, Manual normalized – normalized to total intracranial volume.
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Table 4. 2 Summary of literature review
For articles denoted by * original reported units (ml or cc3) were converted to mm3 . AD-
Alzheimer’s disease; ICC- intra-class correlation coefficient; F-females; M-males; NS – not
significant; N/A – not applicable.
Sample
size
Controls
Hypothalamic
Volume
Study group
Hypothalamic
Volume
Condition Method Intra-rater
Reliability /
ICC
Group
difference
p value
Politis et al.,
2008(Politis,
Pavese et al.
2008)
N=18 728.5 ± 96.02 mm3 609.89± 126.81
mm3
Symptomatic
Huntington's
Manual(Politis
, Pavese et al.
2008)
Not reported 0.06
Koolschijn et
al.,
2008(Koolsch
ijn, van
Haren et al.
2008)*
N=44 1040± 140 mm3 920 ± 140 mm3 Schizophrenia Manual(Pol,
Cohen-
Kettenis et al.
2006)
0.91 P<0.05
Goldstein et
al., 2006
(Goldstein,
Seidman et
al. 2007)*
N=136 780 ± 160 mm3
920 ± 110 mm3
830 ± 170 mm3
1000 ± 120 mm3
Schizophrenia Manual(Goldst
ein, Seidman
et al. 2007)
Not reported
(Inter- rater
0.81)
0.03
Callen et al.,
2004 (Callen,
Black et al.
2004)
N=80 298.6 ± 43.2 mm3 266.5± 54.3 mm3 AD Manual(Callen
, Black et al.
2001)
>0.90 0.002
Buskova et
al., 2006
(Buskova,
Vaneckova et
al. 2006)*
N= 35 798 ± 930 mm3 696± 920 mm3 Narcolepsy/
cataplexy
In-house
combination of
VBM and
manual
<0.01
Peper et al.,
2010(Peper,
Brouwer et
al.)*
N=85 Healthy children
Girls 1010± 90 mm3
Boys 1050 ± 120 mm3
Manual (Pol,
Cohen-
Kettenis et al.
2006)
0.86 N/A
Piquet et al.,
2010(Piguet,
Petersén et
al.)
N=32 Anterior:156±39
mm3
Posterior:193±43
mm3
Anterior: 104 ± 22 -
119±32 mm3
Posterior:104±46 -
149±52 mm3
Fronto-temporal
dementia
Manual
(Piguet,
Petersén et al.)
0.94 Anterior
NS
Posterior
0.04
Hulshoff Pol
et al.,
2006(Pol,
Cohen-
Kettenis et al.
2006)*
N=29 F: 1000 ± 50 mm3
M: 1050± 180 mm3
F: 930± 150 mm3
M: 1070± 130
mm3
Transsexual Manual
(Pol, Cohen-
Kettenis et al.
2006)
0.86 NS
Figure 4. 1 Correlation between methods
Fair correlation between hypothalamic volumes ob
volumetry (r= 0.57 p<0.001); TICV
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tained by atlas-base VBM and manual
– total intracranial volume.
Figure 4. 2 Bland-Altman agreement between methods
Bland-Altman mean difference plot for hypothalamic volume demonstrates
agreement between methods in overall sample and within groups. Atlas
were systematically larger than volumes produced by manual tracing with a trend towards larger
differences between methods for larger hypothalami and better
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-based VBM volumes
agreement for smaller volumes.
acceptable
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Assessment of face validity. A: Example of manual tracing of the hypothalamus on one slice of
an individual image. The same procedure was repeated for the opposite side on each slice (4-6
slices in total) within predefined boundaries. The total volume of the hypothalamus was
calculated in mm3 within demarcated area.
B and C: Colored area represents group average bilateral hypothalamic ROI from WFU Pickatlas
overlaid on the standard MNI brain in the initial larger sample for which hypothalamic volumes
were available. Forty atlas-based VBM volumetry results were randomly selected and 38
included in current report: right - enlarged image.
A B C
Figure 4. 3 Face validity
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Chapter 5 Preface
In the previous chapters we demonstrated that: (i) BMD was reduced in the earliest
clinical stages of AD in both men and women, (ii) BMD was related to whole brain volume and
memory performance in AD, with higher BMD associated with higher whole brain volume (less
brain atrophy) and better memory performance; (iii) hypothalamic volume was associated with
whole body BMD, with lower hypothalamic volumes correlated with reduced BMD in the AD
group by using VBM neuroimaging analyses; and (iv) established automated atlas-based VBM
volumetry as a method of choice in studying the hypothalamic volume.
The findings in Chapters 2&3 suggest that AD-related brain changes specifically in the
hypothalamus are associated with bone health in AD. Bone loss and brain atrophy, however, are
dynamic and change over time. Findings from cross-sectional studies are meant to indirectly
approximate longitudinal changes but their limitation to one time point restricts the ability to
strongly conclude that a longitudinal relationship exists. Thus, we sought to extend our cross-
sectional findings by assessing if similar relationships would be observed over a two-year time
course. Longitudinal relationships between bone loss and hypothalamic atrophy and shared risk
factors for AD and osteoporosis have not been examined in early AD.
In Chapter 5, we present results of a two-year longitudinal study which extends previous
findings of an association between hypothalamic atrophy and bone density and explores
predictors of bone loss in AD.
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Chapter 5
Different Predictors Suggest Different Mechanisms of Bone Loss in Alzheimer’s Disease
Compared to Aging
Loskutova N, Honea R, Burns J (to be submitted to Osteoporosis International, 2011).
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5.1 ABSTRACT
Objective: To assess the relationship of bone loss with brain atrophy and other osteoporotic risk
factors including vitamin D levels, body composition and physical activity in Alzheimer’s
disease (AD) and aging.
Design: Two-year longitudinal case-control study
Participants: Individuals without dementia (Clinical dementia Rating, CDR 0, n=64) and with
early stage AD (CDR 0.5 or 1, n=58) in the University of Kansas Brain Aging Project.
Main outcome measures: Participants were evaluated with dual energy x-ray absorptiometry
(DXA), brain magnetic resonance imaging (MRI), neuropsychological testing and Physical
Activity Scale for the Elderly (PASE) questionnaire at baseline and two-year follow-up. Body
composition, brain atrophy, bone mineral density (BMD), physical activity, and baseline levels
of 25 (OH)D (vitamin D) were measured.
Results: Bone loss was accelerated in AD compared with non-demented controls for the total
body and legs. Vitamin D levels were lower and prevalence of vitamin D deficiency was higher
in AD. Hypothalamic volume was lower in AD at both time points. For AD participants, bone
loss was associated with baseline levels of the vitamin D and hypothalamic atrophy. For non-
demented participants, bone loss was associated with age, female gender and decline in physical
activity.
Conclusion: Risk factors associated with bone loss in non-demented aging were different in AD
and suggest that neurodegeneration and vitamin D deficiency may contribute to bone loss in
early AD.
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5.2 INTRODUCTION
Alzheimer’s disease (AD) and bone loss are two of the most common conditions
associated with aging. Bone loss is associated with a higher prevalence of factures, in particular
hip fractures (Weller and Schatzker 2004). Several large population-based studies reported an
association between hip fractures and AD, placing dementia among the risk factors for fractures
(Friedman, Menzies et al. 2010). On one hand, individuals in all stages of AD have increased
incidence of fractures (Melton, Beard et al. 1994; Sato, Kanoko et al. 2004). Fractures in AD are
associated with poorer recovery and up to four times higher mortality rate at 6 months compared
to cognitively healthy older adults (van Dortmont, Douw et al. 2000; Weller 2000; Xie, Brayne
et al. 2008). Lower bone mineral density (BMD) has also been reported in both men and women
with AD (Sato, Honda et al. 2005; Loskutova, Honea et al. 2009). On the other hand, population
studies suggest that low bone density, one of the major predictors of bone fractures (Ammann
and Rizzoli 2003), and increased rates of bone loss are associated with higher risk of AD (Lui,
Stone et al. 2003; Tan, Seshadri et al. 2005; Zhou, Deng et al. 2010). This evidence suggests that
bone loss may develop years before the AD clinical diagnosis occurs and persists as dementia
progresses. The cause - effect relationship between dementia and fractures remains unknown.
There is a growing body of evidence that risk factors for bone loss including age, decline in
physical activity, impaired nutritional status and deficiency in essential vitamins and
microelements or genetic predisposition are also associated with AD (Friedman, Menzies et al.
2010). These factors are independently associated with both AD and bone loss but the causal
relationship between AD and decline in bone health remains imprecisely defined.
Accumulating evidence suggests that the central nervous system directly regulates bone
health through actions primarily orchestrated by the hypothalamus (Harada and Rodan 2003;
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Takeda 2005; Zaidi 2007), a structure affected early in the AD process (Raskind, Peskind et al.
1999; Callen, Black et al. 2001). The central hypothalamic mechanisms are mediated by leptin, a
fat derived hormone, and appear to affect cortical bone predominantly (Guidobono, Pagani et al.
2006; Murray, Adams et al. 2006; Martin, David et al. 2007; Martin, David et al. 2008).
Therefore, we hypothesize that AD may influence bone density in cortical skeletal sites directly
through pathological changes in the hypothalamus, the major central regulatory structure of bone
remodeling. We previously reported lower BMD in early AD and suggested that brain atrophy,
specifically of the hypothalamus, was associated with lower BMD in AD in a cross-sectional
study. The purposes of this study were 1) to extend previous cross-sectional findings of an
association between hypothalamic atrophy and bone density and 2) to explore predictors of bone
loss in AD in a 2-year longitudinal study. Understanding the association between bone loss and
AD in the context of shared risk factors will help to identify modifiable risk factors and
interventions for reducing bone fractures in a high-risk population of older adults with dementia.
5.3 METHODS
Study participants
Data for this study were collected within the University of Kansas Brain Aging Project, a
case-control study to evaluate the relationship between lifestyle factors and brain aging.
Community dwelling participants 65 years and older residing in the Greater Kansas City
Metropolitan Area were recruited from a referral based memory clinic and by media appeals.
Signed institutionally-approved informed consent was obtained prior to enrollment from all
participants or their legal representatives.
88
Seventy-one patients with early-stage AD (Clinical Dementia Rating (CDR) 0.5, n=57
and CDR 1.0, n=14) and 69 non-demented elderly control participants (CDR 0) were enrolled in
the University of Kansas Brain Aging Project. All participants had standard neurological and
neuropsychological assessment, structural MRI scanning and dual energy x-ray absorptiometry
(DXA) at the baseline and follow-up after two years (mean follow-up time 2.1 [SD 0.2] years) of
study enrollment. Blood samples were collected between 8 and 10 am after overnight fasting,
processed and stored frozen at -80°C. Mini-Mental State Examination (MMSE) was
administered as a standard measure of global cognition (Folstein, Folstein et al. 1975). The
absence or presence and severity of AD were determined by a standard clinical evaluation that
included the CDR and CDR sum of boxes score (Morris 1993). A psychometric battery including
standard tests for memory, executive function and visuospatial ability were administered to every
participant.
Baseline clinical and demographic characteristics of these individuals and detailed
clinical assessment methodology have been reported previously (Burns et al., 2008; Honea et al.,
2009)(Loskutova, Honea et al. 2009). Participants with a history of neurologic disease other than
AD with the potential to impair cognition (i.e., Parkinson disease), current or past history of
diabetes mellitus (defined as a clinical diagnosis, use of an ant-diabetic agent, or 2-hour post-
load serum glucose > 199), recent history of cardiovascular disease (e.g. diagnosis of congestive
heart failure, acute coronary artery event or angina in the 2 years previous to the baseline
evaluation), major depression, use of investigational medications, significant visual or auditory
impairment, systemic illness that may have impaired completion of the study, current or past
history of alcoholism, and MRI exclusions (e.g. pacemakers) were excluded from the study at the
baseline. Participant who did not return for the follow-up DXA assessment and non-demented
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participants converted to AD at the follow-up clinical evaluation were excluded from this study.
The final sample included 58 participants with early AD and 64 non-demented older controls.
Bone density
The BMD was measured for the total body by dual energy x-ray absorptiometry (DXA,
Prodigy fan-beam densitometer, Lunar Corp., GE Medical Systems, Madison, WI). Regions of
interest predominantly composed of either cortical (the legs and total body) or trabecular (the
spine and pelvis) bone obtained from total body BMD measurements were also assessed. The
precision of DXA equipment was assessed by two repeated measurements after repositioning by
the same technician in 15 volunteers (74±11 years old, M/F=7/8) in the KUMC Precision
Assessment of DXA Bone Mineral Density and Total Body Fat Percentage Testing study.
Coefficients of variation (CV) were: 0.9 % for the total body and legs, 2.0% for the pelvis and
3.1% for the spine. The stability of the DXA equipment was checked according to
manufacturer’s instructions. BMD measures in absolute values (g/cm2) at the baseline and two
years were obtained and absolute bone loss in g/cm2 and percent bone loss were computed.
Magnetic resonance imaging and hypothalamic atrophy
Structural MRI data were obtained at the Hoglund Brain Imaging Center with a 3.0 T
Allegra MR scanner (Siemens Medical Solutions, Erlangen, Germany). T1-weighted
magnetization prepared rapid gradient echo (MP-RAGE) sequence (1x1x1mm3 voxels; TR =
2500ms, TE = 4.38ms, TI = 1100ms, FOV 256x256cm2 with 18% oversample, flip angle 8
degrees) were collected and processed for VBM analysis. Every scan was examined for image
artifacts and gross anatomical abnormalities. We used MRIcro® software to reconstruct raw
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Dicom images. Data analysis was performed using the VBM5 toolbox (http://dbm.neuro.uni-
jena.de), an extension of the SPM5 algorithms (Wellcome Department of Cognitive Neurology,
London, UK) running under MATLAB 7.1 (The MathWorks, Natick, MA, USA) on Linux.
Images were modulated and saved using affine registration plus non-linear spatial normalization
(Wilke, Holland et al. 2008), resulting in final tissue maps of grey matter (GM), white matter
(WM), and cerebrospinal fluid (CSF) and smoothed with a 10 mm FWHM Gaussian kernel.
Additionally, for each study participant, total intracranial volume (TICV), total GM, WM, CSF,
and whole brain volumes (GM plus WM) in cm3 were computed using the normalized tissue
maps of each study participant. Finally, the bilateral hypothalami were derived using ROI
approach and the Wake Forest University Pickatlas toolbox (http://www.fmri.wfubmc.edu)
(Maldjian, Laurienti et al. 2003) from the final grey matter tissue maps of each participant
(Loskutova, Honea et al.). Total hypothalamic volumes were computed as a sum of right plus left
and reported in cm3. Same procedures were performed for the baseline and follow-up brain
images. The hypothalamic atrophy was computed as difference in hypothalamic volumes
between evaluations in cm3.
Habitual physical activity level
We used the Physical Activity Scale for the Elderly (PASE) questionnaire to assess
participants’ level of physical activity. In individuals with mild dementia (Vidoni et al, in
review), similar to non-demented older adults (Dinger, Oman et al. 2004), the PASE has been
shown to be valid and reliable measure of habitual physical activity level. The PASE estimates
levels of habitual physical activity based on 7 day reports of the frequency and duration of
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participating in a variety of physical activities. The information provided by the study
participants was used in the analysis. Change in the PASE score between visits was calculated.
Baseline vitamin D levels
Baseline serum level of 25-OHD (vitamin D) were obtained using the DiaSorin Liaison
analyzer for 25-OH Vitamin D TOTAL assay using chemiluminescent immunoassay (CLIA)
technology at the Clinical and Translational Research Center Core Lab at The Children's
Hospital, University of Colorado Denver, Aurora, Colorado. Repeatability of the assay
coefficient of variation in serum samples is 3.0%.
Statistical analysis
Statistical analyses were conducted using SPSS (PASW statists 18, SPSS Inc., Chicago,
Ill). Continuous variables were summarized as means ± standard deviation (SD) and categorical
variables were summarized by ratio. Independent samples t-tests and Mann-Whitney U test were
used for analyzing group differences in continuous variables and chi-square statistics were used
for categorical data. Pared t-test, repeated measures ANOVA or Wilcoxon Signed Rank exact
test for two-related samples (longitudinal) two-tailed were used to determined change in
measured variables over two years as deemed appropriate. Pearson and Spearman correlations
were used to investigate the univariate relationships between predictors and bone density.
Stepwise backward elimination linear regression was used next for multivariate analyses. All
variables that correlated at a trend level (p<0.10) in the univariate analyses were included in the
stepwise multiple regression analysis.
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5.4 RESULTS
Bone loss is accelerated in AD
The baseline and follow-up characteristics for participants in the study are presented in
Table 1. There was no difference in age and gender distribution between the groups at baseline
and follow-up. BMD declined from baseline in both groups (p <0.05) with greater bone loss in
AD compared to the non-demented controls in total body (2.10% in AD vs. 0.95% in non-
demented, p=0.03, Figure 1) and leg BMD (3.18% in AD vs. 1.68% in ND, p=0.03). There was
no difference in the baseline BMD or rate of bone loss in the spine, trunk, or pelvis between the
groups. Since gender is the main determinant of bone density and our sample was mixed, we
next looked at the rate of bone loss in men and women with and without dementia separately.
Significant decline in total BMD was observed in both men and women with AD (p < 0.05) and
non-demented women (p< 0.05). BMD in non-demented men was unchanged (p=0.16) over two
years. When compared within genders (Figure 2), women with AD lost more total body BMD
than women without dementia (2.82% vs. 1.96%) over two years although this difference was
not significant (p=0.16). Men with AD lost more total body BMD over two years (decline by
1.18%, p=0.003) than men without dementia. The total body BMD loss values were smaller in
respect to the LSC (0.9*2.77=2.6%) in all but women with AD.
Decline in physical activity in both groups
The average baseline level of physical activity of the control group was comparable to
that reported for community dwelling elderly persons in the US (Washburn, McAuley et al.
1999) (PASE score =130.7±55.5). Baseline habitual physical activity level was lower in AD
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(102.8±76.5 p=0.02) than in non-demented. Both groups declined over two years and there was a
trend to greater decline in physical activity in AD vs. non-demented (p=0.07).
Lower levels of vitamin D in AD
In the overall cohort 23.4% or participants were vitamin D deficient (<20 ng/ml) and
21.8% had sufficient levels of vitamin D (≥ 30 ng/ml), consistent with population studies (Holick
2007). As shown in Figure3, a higher prevalence of vitamin D deficiency was observed in the
early AD group (N=17 (36.2%) in AD vs. N=7 (12.3%) in non-demented, p<0.05). Baseline
serum level of vitamin D (25 OHD) was lower on average in early AD compared to controls
(24.1±8.7 vs. 27.4±8, p=0.04).
Whole brain and hypothalamic atrophy
As expected, whole brain atrophy rate was higher in AD (2.2% vs. 1.2% in non-demented
per year, p<0.001). Whole brain atrophy however did not correlate with bone loss in either
group. Hypothalamic volumes were smaller in AD group at baseline (0.65 ±0. 10 cm3 vs. 0.72 ±
0.12 cm3 in non-demented, p=0.001) consistent with previously reported results (Loskutova,
Honea et al.), and follow-up (0.54 ± 0. 82.1 cm3 in AD vs. 0.58 ± 0.78 cm3 in non-demented,
p=0.006). Hypothalamic atrophy correlated with whole brain atrophy (r= 0.21, p=0.05) in the
overall group but not when analyzed separately in non-demented and AD. Hypothalamic atrophy
(volume difference between gender and age adjusted T1 and T2 hypothalamic volume)
correlated with total BMD loss in AD group at a trend level r=0.29, p=0.07, but not in non-
demented (r = - 0.005, p=0.97).
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Changes in body composition
Groups were similar in measures of adiposity: BMI, percent body fat, and waist-to-hip
circumference ratio between the groups at baseline. Over two years however, the AD group had
a slight increase in the percent body fat (34.9 ± 11.1 vs. 34.0 ± 10.4 at baseline, p<0.05) and
waist-to-hip circumference ratio (0.91 ± 0.07 vs. 0.87 ± 0.08 at baseline, p<0.001) while no
change was found in non-demented controls.
Predictors of bone loss
We correlated changes in total body BMD with baseline measures of vitamin D,
demographic characteristics, baseline levels of physical activity, two-year change in physical
activity, adiposity, whole brain atrophy, and hypothalamic atrophy. Analyses were conducted
within groups (AD and non-demented) due to group differences in bone loss across groups.
Next, all variables that correlated with bone loss at a trend level (p<0.10): age, gender, and
change in physical activity, hypothalamic atrophy and baseline levels of vitamin D were entered
in a backward linear regression analysis. Backward linear regression analysis demonstrated
(Table 2) that in the non-demented group, decline in the total body BMD was related to decline
in physical activity (β = 0.23, p = 0.09), age (β= - 0.31, p = 0.02) and female gender (β = - 0.32,
p = 0.02), together explaining 28% of total variance in bone loss.
In the AD group, decline in the total body BMD was associated with lower baseline
vitamin D level (β = - 0.41, p = 0.02, Figure 4) and hypothalamic atrophy (β = 0.30, p = 0.06,
Figure 5), which together explained 23.1% of total variance in bone loss.
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5.5 DISCUSSION
In non-demented aging, we found as expected that the canonical triad of age, female
gender and physical decline predicted rate of bone loss, consistent with the well-established
literature demonstrating these three factors as the major predictors of bone loss with age
(Gudmundsdottir, Oskarsdottir et al. ; Bakhireva, Barrett-Connor et al. 2004; Havill, Mahaney et
al. 2007). In early AD, however, bone loss was observed in both men and women and was not
related to physical activity or age. Rather, bone loss in AD was associated with baseline vitamin
D level and hypothalamic atrophy suggesting that mechanisms influencing bone loss in AD may
be different form bone loss in normal aging.
Vitamin D availability is one of the major modulators of bone health (Holick 2006). It
has been suggested that circulating vitamin D levels above 20 ng/ml are necessary to support
normal bone health in the general population (Holick 2007). Our findings suggest vitamin D
deficiency (circulating 25 (OH) vitamin D level below 20 ng/ml) is more prevalent in AD than
non-demented controls. Low levels of Vitamin D have been associated with AD (Buell, Dawson-
Hughes et al. ; Kipen, Helme et al. 1995; Sato, Asoh et al. 1998; Oudshoorn, Mattace-Raso et al.
2008), although whether vitamin D influences AD risk or, alternatively, AD related changes
influence vitamin D levels or its metabolism remains unknown. Our data suggest that even
though on average both groups fell into vitamin D insufficient category (circulating 25 (OH)
vitamin D level between 20 and 30 ng/ml) the observed lower Vitamin D in AD may be
clinically relevant given its linear association with BMD loss in this group of participants.
Recent evidence indicates that in addition to its bone benefits in aging (Holick 2006), vitamin D
has a positive effect on muscle mass, physical performance, cognition, inflammation, and
neuronal survival (Adams and Hewison 2010; Nimitphong and Holick 2011). Therefore, our
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observations may have therapeutic relevance as our data suggest vitamin D replacement may be
relatively more important in AD, in particular AD men, though further randomized controlled
trials will be necessary to determine this.
Bone loss in AD was observed despite an increase in measures of adiposity over two
years. This is interesting given well-described associations between higher BMD in obesity and
protective effects of fat on bone mass (Reid 2010). Why bone loss was observed in the presence
of increasing adiposity is unknown. Bone loss in AD was not explained by actual changes in
adiposity measures, suggesting that mechanisms mediating relationships between fat and bone
may be different in AD and obesity. Several potential mechanisms could explain our
observations. Leptin, a hormone produces by adipose tissue, is involved in regulation of bone
remodeling and energy metabolism (Takeda, Elefteriou et al. 2002). Levels of leptin correlated
highly with fat mass with increase in fat leading to elevated levels of leptin (Solin, Ball et al.
1997). Leptin via central regulatory mechanisms orchestrated by the hypothalamus inhibits bone
formation (Elefteriou, Takeda et al. 2004). The precise mechanisms of bone loss in
neurodegeneration however are still unclear and need further exploration. Previously published
reports on pathological changes and atrophy in the hypothalamus, high levels of leptin and
increased sympathetic tone in AD (Gil-Bea, Aisa et al. ; Standaert, Lee et al. 1991; Swaab,
Goudsmit et al. 1992; de Lacalle, Iraizoz et al. 1993; Pascualy, Petrie et al. 2000; Callen, Black
et al. 2001) together with our observations of a relationship between the hypothalamus atrophy
and bone loss suggest a possibility that disruption of central hypothalamic regulatory
mechanisms of energy expenditure and bone mass may be one of the potential mechanisms of
bone loss in AD.
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The current study is limited by its observational nature and future interventional studies
will be necessary to define the mediating mechanisms of the relationship between bone density
and AD. The participants in the study were a convenient sample of Caucasian race, which limits
generalizebility of our findings. Also, the relatively small sample size could limit the power to
observe group differences or relationships between important factors. Nevertheless, our data
extend previous work and suggest that bone loss is accelerated in AD and hypothalamic atrophy
and vitamin D insufficiency may contribute to bone loss in early AD.
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Table 5. 1 Sample characteristics
Data represent means ± SD unless otherwise stated; AD – Alzheimer’s disease; MMSE – Mini
Mental State Exam;
BMI – body mass index; *P 0.05; **P0.001; ***P0.0001, tP<0.10 – trend; ns P>0.10
baseline 2 years baseline baseline 2 years D
Age,y 73.8 ±
6.8
75.4 ±
6.3
ns
Gender, F/M 34/29 33/25 ns
Vitamin D,
ng/ml
27.5 ±
8.0
24.1 ±
8.7
*
MMSE 29.4 ±
0.8
29.2 ±
1.3t
26.2 ±
3.1
*** *** ***
Physical
Activity
130.7 ±
55.5
121.8 ±
58.5
103.4 ±
75.9
* *** t
BMI 26.2 ±
3.8
25.8 ±
3.8*
25.8 ±
3.8
ns ns t
Body fat, % 33.6 ±
8.8
33.5 ±
8.9
34.0 ±
10.4
ns ns *
Waist/hip
circumference
0.87 ±
0.10
0.88 ±
0.08
0.87 ±
0.08
ns t *
Total body 1.16 ±
0.11
1.15 ±
0.12**
1.12 ±
0.12
Legs 1.26 ±
0.16
1.24 ±
0.18***
1.21 ±
0.17
Spine 1.09 ±
0.18
1.09 ±
0.20
1.05 ±
0.18
Pelvis 1.09 ±
0.14
1.06 ±
0.17***
1.06 ±
0.14
1.17 ±
0.18*** *
1.06 ±
0.18 ns
1.04 ±
0.14* ns
34.9 ±
11.1*
0.91 ±
0.07***
1.10 ±
0.13*** *
∆ p valueBone density, g/cm
2
22.4 ±
7.2***
75.6 ±
64.4**
25.9 ±
4.3
Non-demented
(n=64)
Early AD (n=58) Between group difference
2 years
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Table 5. 2 Predictors of bone loss
Bone loss, ND
(g/cm2)
Bone loss, AD
(g/cm2)
Age -0.31* -
Gender -0.32* -
 Physical Activity 0.23
t
-
Baseline Vitamin D - -0.41*
 Hypothalamic Volume - 0.30
t
Predictors of bone loss (standardized coefficients, β) in aging and early Alzheimer’s disease
*P 0.05; t P<0.10 – trend
Figure 5. 1 Two-year bone loss
Bone loss (percent from the baseline) is accelerated in AD
(*p=0.03).
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compared to non-demented aging
Figure 5. 2 Bone loss in women and men with and without AD
Bone loss in women and men with and without AD; bone loss in men is accelerated in
Greater bone loss was observed in
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men with AD compared to non-demented men
AD.
(**p=0.003).
Figure 5. 3 Vitamin D status in non
Prevalence of vitamin D deficiency is higher
OH D >30ng/ml) are lower in AD
deficient (25 OHD <20 ng/ml) when
participants were either vitamin D sufficient
between 20 and 29 ng/ml, p<0.05
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-demented and AD
and adequate levels of vitamin D (sufficiency, 25
. Higher numbers of participants with AD were
compared to non-demented. More non
or had intermediate vitamin D levels (25 OH D
for all).
vitamin D
-demented
Figure 5. 4 Correlation of bone loss
Relationship between baseline vitamin D levels and total body bone loss
(dotted line) and early AD groups
bone loss in AD but not in non
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with vitamin D
in the
(solid line). Higher vitamin D levels are associated with less
-demented controls.
non-demented
Figure 5. 5 Correlation of bone loss and hypothalamic atrophy
Relationship between baseline hypothalamic atrop
non-demented (dotted line) and early AD g
associated with higher percent bone loss from the baseline in AD but not in non
controls.
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hy levels and total body bone loss (%) in
roups (solid line). Greater hypothalamic atrophy is
the
-demented
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Chapter 6 Preface
In the previous chapter we reported that hypothalamic atrophy and vitamin D levels were
associated with bone loss in early AD but not in non-demented aging. We also discussed several
potential mechanisms to explain these relationships including the one that is the main focus of
this work – involvement of central regulatory mechanisms mediated by neural (leptin) and
neurohumoral (GH-IGF-1) factors. In Chapter 6 we extend our previous finding of an association
between hypothalamic atrophy and bone loss and explore roles of leptin and IGF-1 as potential
mediating factors between AD related hypothalamic atrophy and bone loss.
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Chapter 6
Role of Central Hypothalamic Mechanisms in Bone Loss in Alzheimer’s Disease: Testing a
Path Model
Loskutova N, Burns J (to be submitted, 2011)
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6.1 ABSTRACT
Aim: To test a model that assesses the role of hypothalamic atrophy in bone loss in Alzheimer’s
disease (AD) and potential mediators through neural (leptin) and neurohumoral (insulin-like
growth factor –1, IGF-1) mechanisms.
Background: Animal studies provide strong evidence that the CNS directly regulates bone
remodeling through the actions of the hypothalamus via two distinct pathways, the neural
(mediated by leptin) and neurohumoral (mediated by neurohormones and growth factors) arms.
The impact of AD on central regulatory mechanisms on bone mass is not known.
Methods: The proposed model was developed using a conceptual framework based on
previously established evidence to assess the role of hypothalamic atrophy in bone loss. The data
were collected as a part of the University of Kansas Brain Aging Project, a two year
observational study of older adults with early stage AD and non-demented controls.
Demographic characteristics and measures of bone density, body composition, and hypothalamic
volume, serum levels of leptin, growth hormone, vitamin D and IGF-1 were collected. Data
analysis included descriptive statistics, correlation techniques and path analysis.
Results: Hypothalamic atrophy had a direct effect on bone loss. The indirect effect was small
due to absence of independent associations between IGF-1 or leptin with bone loss. Leptin
increased over two years in AD and the increase in leptin was associated with both hypothalamic
atrophy and declines in IGF-1.
Conclusions: The results of our study suggest that central regulatory mechanisms of bone mass
may be disturbed by neurodegeneration and contribute to bone loss in participants in the early
stages of AD. Further studies are needed to explore the role of brain atrophy in bone loss.
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6.2 INTRODUCTION
Alzheimer’s disease (AD) and bone loss are two of the most common conditions
associated with aging. Low bone mineral density (BMD) and increased rates of bone loss are
associated with cognitive decline and a higher risk of developing AD (Yaffe, Browner et al.
1999; Tan, Seshadri et al. 2005; Zhou, Deng et al. 2010). Individuals with all stages of AD have
lower bone density and an increased incidence of fractures (Melton, Beard et al. 1994). Fractures
in AD are associated with poorer recovery (van Dortmont, Douw et al. 2000) and up to four
times higher mortality rate at 6 month compared to cognitively healthy older adults who suffer
fractures (Nightingale, Holmes et al. 2001). Bone loss may occur years before the onset of
cognitive manifestations and a clinical diagnosis of AD and appears to persist as dementia
progresses. Multiple factors have been postulated to explain the association between bone loss
and AD, including shared common risk factors, such as age, estrogen exposure, genetic
predisposition, and low physical activity, nutritional, dietary, and environmental factors
(Friedman, Menzies et al. 2010). These factors are independently associated with both AD risk
and bone loss although the causal relationship between AD and decline in bone health remains
unclear.
Animal studies provide strong evidence that the CNS directly regulates bone remodeling
through the actions of the hypothalamus via two distinct pathways, the neural and neurohumoral
arms (Harada and Rodan 2003; Takeda 2005). Briefly, the neural arm involves hypothalamic
control of bone remodeling through increased sympathetic nervous system (SNS) output
mediated by leptin. Leptin’s actions are mediated by its receptor in the the ventro-medial
hypothalamus that regulates SNS output. Activation of the SNS reduces osteoblast proliferation
and bone formation via β2 adrenoreceptors on osteoblasts. The neurohumoral arm involves
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hypothalamic control of the anterior pituitary hormones, such as growth hormone (GH) and its
executive mediator insulin-like growth factor-1 (IGF-1). IGF-1 plays an important role in the
stimulation of osteoblastic function, bone matrix collagen synthesis and bone formation (Murray,
Adams et al. 2006).
The evidence of AD-related dysfunction in both the neurohumoral and neural arms is
abundant. Dysfunction of the hypothalamo-pituitary axis and activity of the SNS are reported in
AD. For instance, GH and IGF-1 levels ( Alvarez 2007; (Gomez 2008) are reduced in AD.
Profound deficits have been reported in the IGF-1 receptors and signaling in the postmortem AD
brains (Steen 2005, Moloney 2008). Additionally, several studies demonstrated evidence of
increased sympathetic activity (Pascualy, Petrie et al. 2000) including increased brain
noradrenergic activity and elevated serum and cerebrospinal fluid levels of norepinephrine
(Raskind, Peskind et al. 1984; Elrod, Peskind et al. 1997; Raskind, Peskind et al. 1999). Current
reports on association between leptin levels and BMD in humans however, are highly
contradictory (Cock and Auwerx 2003) and range from negative (Oh, Lee et al. 2005; Maimoun,
Coste et al. 2008) or no association (Di Carlo, Tommaselli et al. 2007; Peng, Xie et al. 2008) to
positive relationships (Zoico, Zamboni et al. 2008; Oguz, Tapisiz et al. 2009), suggesting a clear
need in further studies.
We previously demonstrated that low bone density and bone loss in AD were associated
with atrophy of the hypothalamus and proposed a hypothesis that AD-related hypothalamic
structural change alters neural and neurohumoral regulatory systems of bone remodeling and
contributes to bone loss in early AD. The purpose of this study was to extend previous
observations by assessing the roles of leptin and GH-IGF-1 in mediating relationship between
hypothalamic structural changes and bone loss in AD.
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6.3 DATA COLLECTION AND METHODS
Study participants and demographics
Data for this study were collected within the University of Kansas Brain Aging Project, a
case-control, 2-year longitudinal study assessing the role of lifestyle factors in brain aging.
Community dwelling participants 65 years and older residing in the Greater Kansas City
Metropolitan Area were recruited from a referral based memory clinic and by media appeals.
Signed institutionally-approved informed consent was obtained prior to enrollment from all
participants or their legal representatives.
Seventy-one patients with early-stage AD (Clinical Dementia Rating (CDR) 0.5, n=57
and CDR 1.0, n=14) and 69 non-demented elderly control participants (CDR 0) were enrolled in
the University of Kansas Brain Aging Project. All participants had standard neurological and
neuropsychological assessment, structural MRI scanning and dual energy x-ray absorptiometry
(DXA) at baseline and two years later (mean follow-up time 2.1 [SD 0.2] years). Blood samples
were collected between 8 and 10 am after overnight fasting, processed and stored frozen at -
80°C. Mini-Mental State Examination (MMSE) was administered as a standard measure of
global cognition (Folstein, Folstein et al. 1975). The absence or presence and severity of AD
were determined by a standard clinical evaluation that included the CDR and CDR sum of boxes
score (Morris 1993). A psychometric battery including standard tests for memory, executive
function and visuospatial ability was administered to every participant.
Baseline clinical and demographic characteristics of these individuals and detailed
clinical assessment methodology have been reported previously as part of a larger cohort (Burns
et al., 2008; Honea et al., 2009). Participants with a history of neurologic disease other than AD
with the potential to impair cognition (i.e., Parkinson disease), current or past history of diabetes
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mellitus (defined as a clinical diagnosis, use of an ant-diabetic agent, or 2-hour post-load serum
glucose > 199), recent history of cardiovascular disease (e.g. diagnosis of congestive heart
failure, acute coronary artery event or angina in the 2 years previous to the baseline evaluation),
major depression, use of investigational medications, significant visual or auditory impairment,
systemic illness that may have impaired completion of the study, current or past history of
alcoholism, and MRI exclusions (e.g. pacemakers) were excluded from the study at the baseline.
Participant who did not return for the follow-up DXA assessment and non-demented
participants converted to AD at the follow-up clinical evaluation were excluded from this study.
The final sample included 57 participants with early AD and 64 non-demented individuals.
Bone density and body composition
We used dual energy x-ray absorptiometry (DXA, Prodigy fan-beam densitometer, Lunar
Corp., GE Medical Systems, Madison, WI) to assess body composition and total body BMD.
The precision of DXA equipment was assessed by two repeated measurements after
repositioning by the same technician in 15 volunteers (74±11 years old, M/F=7/8) in the KUMC
Precision Assessment of DXA Bone Mineral Density and Total Body Fat Percentage Testing
study. Coefficient of variation for the total body BMD was 0.9 %. The stability of the DXA
equipment was checked according to manufacturer’s instructions. BMD measures in absolute
values (g/cm2) at the baseline and two years were obtained. Bone loss was measured as an
absolute bone loss in g/cm2 (baseline minus follow-up measures, higher positive values = more
loss) and ∆ BMD in percent as Δ BMD= (BMD1−BMD0) /BMD0×100%, where BMD0 is a
baseline measure and BMD1 is a follow-up measure (higher negative values = more loss).
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Magnetic resonance imaging and hypothalamic atrophy
Baseline and follow-up whole brain structural MRI data were obtained at the Hoglund
Brain Imaging Center with a 3.0 T Allegra MR scanner (Siemens Medical Solutions, Erlangen,
Germany). T1-weighted magnetization prepared rapid gradient echo (MP-RAGE) sequence
(1x1x1mm3 voxels; TR = 2500ms, TE = 4.38ms, TI = 1100ms, FOV 256x256cm2 with 18%
oversample, flip angle 8 degrees) were collected and processed for VBM analysis. Every scan
was examined for image artifacts and gross anatomical abnormalities. We used MRIcro®
software to reconstruct raw Dicom images. Data analysis was performed using the VBM8
toolbox (http://dbm.neuro.uni-jena.de), an extension of the SPM8 algorithms (Wellcome
Department of Cognitive Neurology, London, UK) running under MATLAB 7.2 (The
MathWorks, Natick, MA, USA) on Linux. Images were modulated and saved using affine
registration plus non-linear spatial normalization (Wilke, Holland et al. 2008), resulting in final
tissue maps of grey matter (GM), white matter (WM), and cerebrospinal fluid (CSF) and
smoothed with a 10 mm FWHM Gaussian kernel. Additionally, for each study participant, total
intracranial volume (TICV), total GM, WM, CSF, and whole brain volumes (GM plus WM) in
cm3 were computed using the normalized tissue maps of each study participant. Finally, the
bilateral hypothalami were derived using ROI approach and the Wake Forest University
Pickatlas toolbox (http://www.fmri.wfubmc.edu) (Maldjian, Laurienti et al. 2003) from the final
grey matter tissue maps of each participant. Total hypothalamic volumes were computed as a
sum of right plus left and reported in cm3. Same procedures were performed for the baseline and
follow-up brain images. The detailed procedure for MRI acquisition and VBM processing for the
baseline brain images of study participants has been previously reported (Loskutova, Honea et
113
al.). The hypothalamic atrophy was computed as difference in hypothalamic volume in cm3
(baseline minus follow-up, higher positive values=more atrophy).
Blood sampling and analysis
Venous blood samples were collected at the baseline and follow-up visits between 8 and
10 am after overnight fasting, processed and stored frozen at -80°C. Baseline serum level of 25-
OHD were obtained using the DiaSorin Liaison analyzer for 25-OH Vitamin D total assay using
chemiluminescent immunoassay (CLIA) technology. Repeatability of the assay coefficient of
variation in serum samples is 3.0%. Total serum IGF-1 levels were determined using human
IGF-1 ELISA kit (Diagnostic Systems Laboratories, Inc. Texas, USA) with sensitivity of15
ng/ml and precision of 5.0%. Leptin was determined by radioimmunoassay (RIA, Beckman
Coulter, Inc., California, USA). The sensitivity of the essay is 0.5 ng/ml and precision is 5.9%.
The Growth Hormone (GH, HGH) levels were determined by the Human Growth Hormone
ELISA kit (Diagnostic Systems Laboratories, Inc. Texas, USA) with sensitivity of 0.03 ng/ml
and precision of 5.0%. All analyses were done at the Clinical and Translational Research Center
Core Lab and The Children's Hospital, University of Colorado Denver, Aurora, Colorado.
Change (∆) in leptin and IGF-1 was computed as an absolute change in ng/ml (baseline minus
follow-up). For ∆ leptin higher negative values = more increase in leptin levels; for ∆ IGF-1
higher positive values = more decline in IGF-1 levels over two years.
Statistical Analysis
Statistical analyses were conducted using SPSS (PASW statists 18, SPSS Inc., Chicago,
Ill). Continuous variables were summarized as means ± standard deviation (SD) and categorical
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variables were summarized by ratio. Independent samples t-tests and Mann-Whitney U test were
used for analyzing group differences in continuous variables and chi-square statistics were used
for categorical data. Pared t-test, repeated measures ANOVA or Wilcoxon Signed Rank exact
test for two-related samples (longitudinal) two-tailed were used to test change in measured
variables over two years as deemed appropriate. Pearson and Spearman correlations were used to
investigate the univariate relationships between variables.
Path analyses and hypothetical model
Development of the model of effects of neurodegeneration on central control of bone
remodeling via neural and neurohumoral hypothalamic regulatory arms was based on a series of
animal studies confirming such biological regulatory mechanisms (Takeda 2005), evidence of
hypothalamic structural damage and dysfunction in AD and our prior observations of an
association between hypothalamic atrophy and bone loss. The hypothetical model was tested by
using path analysis. Path analysis is closely related to multiple regression analysis and referred to
as causal modeling technique. The causal assumptions (what causes what) are shown in the path
diagram by arrows. It is best suited for testing a complex a priori theoretical model and can be
used to explain the interrelationships among a set of observed variables, as well as to evaluate
the relative importance of each variable in the model in a certain observed variable, through the
use of direct and indirect effects. This type of analysis allows exploring direct and indirect
relationships even when one variable may not have a direct effect, but it may have an indirect
effect. We tested the basic model of the hypothalamic control of bone mass in non-demented
aging and in AD (Figure 1). The hypothetical model included direct effects of hypothalamic
atrophy on bone loss and indirect effects mediated by
neurohumoral (GH-IGF-1) regulatory arms of hypothal
Figure 6. 1 Basic hypothetical model of the relationship between hypothalamic atrophy and bone
loss; GH-growth hormone; IGF
The analysis was done using the Amos™ 17.0, an extension of SPSS statistical software
(SPSS Inc., Chicago, Ill). The goodness
within each model. For relationships with known statistical and biological directionali
significance level set as one-tailed p
of a model included a chi-squire goodness
indices > 0.9, root mean square error of approximation
6.4 RESULTS
Sample characteristics
The baseline and follow
Tables 1 and reported in details previously (Chapter 5).
gender distribution, between the groups at the baseline and follow
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changes in neural (leptin
amic control of bone remodeling.
-1- insulin-like growth factor-1
-of-fit, standardized (β-values), and p
≤ 0.05 was considered significant. The indicator of good fit
- of - fit, comparative fit (CFI) and normed fit (NFI)
(RMSEA) <0.05 and Hoelter’s N >200.
-up characteristics for participants in the study are presented in
There was no difference in age and
-up. As previously reported,
) and
-values are reported
ty,
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BMD declined from baseline in both groups with greater bone loss in AD compared to the non-
demented controls in total body BMD (2.10% in AD vs. 0.95% in non-demented, p=0.03).
There was no difference in the adiposity measures (BMI or percent body fat) at baseline
between the groups. Over two years, however, the AD group had a slight increase in the percent
body fat (34.8% ± 11.14 at follow-up vs. 34.0% ± 10.42 at the baseline, p<0.05). Change in
percent body fat (∆ body fat) over two years differed between group (p<0.05). There was no
difference between the groups at baseline in measures of serum leptin, total IGF-1, and growth
hormone. Levels of IGF-1 declined slightly but equally over two years in both groups. Leptin
levels in the control group remained unchanged over two years (13.1± 10.3ng/ml at baseline vs.
13.3 ± 10.0ng/ml at follow-up, p=0.84). In the AD group leptin levels increased significantly
(14.9 ± 11.5 ng/ml vs. 21.9 ± 19.8 ng/ml at follow-up, p<0.001).
BMD and bone loss correlates
The relationships among body composition variables, serum levels of IGF-1, leptin,
growth hormone and vitamin D, hypothalamic volume and bone density were analyzed using
Pearson’s correlation coefficients. Baseline and change over time correlates of total body BMD
and ∆BMD are presented in the tables 2&3.  Due to significant correlation between leptin and
body fat, the levels of leptin were corrected for total fat mass in further analysis.
Path analysis
Based on the correlation matrix and the theoretical relationships among variables we
tested the hypothetical model using simultaneous regression models in path analysis. As reported
in our previous study, low baseline vitamin D levels (25-OHD) were associated with bone loss in
AD (Chapter 5). This relationship is clinically and biologically important, thus baseline vitamin
D levels were added to the model. No relationship was observed between baseline growth
hormone levels and the dependent variable (bone density or bone loss) or mediating independent
variables (leptin, IGF-1 or vitamin D), therefore GH was excluded from the initially
model. The variables of interest met the normal distribution assumption and were entered into
the initial full model based on the theoretical or clinical importance and for assessment of
covariances and possible indirect effects.
effects of variables in the model on bone loss
of all four independent variables (hypothalamic atrophy, vitamin D,
bone loss and additionally tested covariances in a stepwise manner. We found that
atrophy and vitamin D had direct effects on bone loss
not. Additionally, correlations existed between 1). hypothalamic atrophy and leptin change and
2). leptin change and change in IGF
Next, we adjusted the model
had any indirect effect on bone loss through
change) or neurohumoral arm (IGF
Figure 6. 2 Intermediate hypothetical model of the relationship between hypothalamic atrophy
and bone loss; IGF-1- insulin-
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We compared path coefficients to explore relative
. We started with the model tha
 leptin, and
while leptin change and IGF
-1.
(Figure 2) and investigated whether hypothalamic atrophy
either changes observed in the neural arm (leptin
-1 change) independently.
like growth factor 1, vitamin D was also included in the model.
proposed
t tested direct effects
IGF-1) on
hypothalamic
-1 change did
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As a result, no indirect effect of hypothalamic atrophy on bone was observed through
either IGF-1 change or leptin change alone. Vitamin D demonstrated a direct effect only and did
not mediate any other relationships in the model. Interestingly, in our model leptin change did
not have a direct effect on bone loss, however, it independently correlated with change in IGF-1
and hypothalamic atrophy. Therefore, we tested an alternative biologically plausible model that
examined the potential role of changes in leptin and IGF-1 on bone loss (Figure 3). The final
model examined four predictors of bone loss (%, dependent variable, 2.  BMD). The predictors
(or independent variables) included in the model were: 1. Hypothalamic Atrophy, 3. Vitamin D,
4.  Leptin, and 5.  IGF-1.
For the AD group, in this model 20 % of the total variance in bone loss ( BMD) was
explained. Hypothalamic Atrophy had a direct effect (β = - 0.28, p=0.001) and a small indirect
effects (β = -0.02) through both leptin and IGF-1 simultaneously on bone loss ( BMD). Indirect
effects are obtained by multiplying the effects along each indirect path. Total effect of
Hypothalamic Atrophy on bone loss ( BMD, [the direct effect of hypothalamic atrophy (β = -
0.28) added to the indirect effect (β = -0.02) via modifying independent variables]) was (β =-
0.30). Effects of Vitamin D were direct and independent of other independent variables in the
model (β =0.29). In the model, Hypothalamic Atrophy explained 5% of the total variance in 
Leptin. Increase in leptin ( Leptin) explained 17 % in total variance in decline in IGF-1 ( IGF-
1). Relationship between change in IGF-1( IGF-1) and bone loss ( BMD) was not significant,
however. The alternative model provided a good fit for the data (χ2 = 2.0, df =5, p= 0.85; CFI =
1.0; NFI = 0.93; RMSEA <0.001 CI = 0.00-0. – 0.10; Hoelter’s N = 313). None of the tested
models fit the data in the non-demented group.
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6.5 DISCUSSION
In our previous work, we demonstrated a relationship between bone loss and
hypothalamic atrophy in the earliest clinical stages of AD in cross-sectional and longitudinal
studies (Loskutova, Honea et al. 2009) and (Chapter 5). No association between hypothalamic
volume and bone density or loss was observed in non-demented controls. Here, we tested a
hypothesis that neurodegenerative changes in AD may influence bone mass via alteration in
central regulatory mechanisms of bone remodeling. We observed moderate effects of
hypothalamic atrophy on bone loss (total β=-0.30) with a direct effect due to unexplained factors
and found evidence of small and incomplete indirect mediation through leptin and IGF-1. As
expected, more atrophy in the hypothalamus was associated with: 1). accelerated bone loss and
2). increase in lepin over two years. The observed increase in leptin was also associated with
decline in IGF-1, consistent with previous studies (Milewicz, Krzysiek et al. 2005).
Genetic and pharmacological manipulations in animal models are converging with
clinical and epidemiological observations in humans to suggest the importance of central
regulation of bone homeostasis through hypothalamic control via both neural pathways and
hypothalamo-pituitary hormonal mechanisms (Takeda 2005). Leptin acts on the
leptinergic/peptidergic neurons in the ventro-medial hypothalamus (VMH) to activate
sympathetic nervous system (SNS) output. SNS output activates β -2-adrenoreceptors on the
osteoblasts and results in decreased proliferation and bone formation. Additional mediators of
leptin’s effects on bone have also been identified and include serotonin, CART (cocaine
amphetamine regulated transcript), Neuromedin U and neuropeptide Y (Wei and Ducy 2010).
Peripheral circulating leptin levels may serve as a regulation threshold that initiates central
cascade mechanisms through a variety of signaling mechanisms to negatively influence bone
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formation via central regulatory control in the ventro-medial hypothalamus(Martin, David et al.
2008). The neurohumoral arm is an additional mechanism through which the hypothalamus
controls bone remodeling via regulation of neurohormones and growth factors. Leptin influences
levels of IGF-1 with numerous studies reporting an inverse relationship between leptin and IGF-
1(Milewicz, Krzysiek et al. 2005; Martin, David et al. 2007). Various unobserved mechanisms
involved in hypothalamic control of bone mass may explain the direct effect of hypothalamic
atrophy and some of the unexplained variance in bone loss in AD.
Our initial understanding of separate neural and neurohumoral/hormonal mechanisms led
us to hypothesize that the relationship between hypothalamic atrophy and bone loss would be
mediated by two separate paths: through decline in IGF-1 and through increase in leptin. Our
results however suggest that that relationship between hypothalamic volume loss and bone loss
was not mediated by either an increase in leptin or decline in total IGF-1. Our results rather
imply that hypothalamic atrophy was associated with an increase in leptin levels over two years
that may have mediated a decline in IGF-1. In our study, the peripheral leptin levels increased
significantly in AD participants but not in non-demented controls over two years. Levels of IGF-
1 declined over time and, consistent with previous literature, were related to increases in leptin
(Milewicz, Krzysiek et al. 2005). Why increased level of leptin were observed in our study
remains unclear, but may be related to abnormal functioning of hypothalamus regulated
timekeeping and clock genes (e.g. nocturnin) that are found to be involved in shifting
differentiation of mesenchymal stem cells towards adipogenesis in aging (Kawai, Green et al. ;
Kawai, Green et al. ; Kirkland, Tchkonia et al. 2002; Moerman, Teng et al. 2004).
Decline in IGF-1 however was not related to bone loss, which is interesting given well-
described effect of IGF-1 on bone mass (Yakar, Courtland et al.). Lack of an association between
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IGF-1 and bone has been reported in several studies. For example, in a study of 123
postmenopausal women IGF-1 did not have a direct effect on measured parameters of bone
density or bone turnover (Martini, Valenti et al. 2001). We speculate that in our study this could
be due to several possible mechanisms. It is possible that our model is missing an important link
that mediated a relationship between bone and peripheral total IGF-1. Since we only measured
total IGF-1 (a complex of free IGF-1 and its binding proteins), imbalance in the IGF-1 system
components perhaps is more important in assessing anabolic effects of IGF-1 (Mohan, Farley et
al. 1995). Highly elevated levels of IGF-1 binding proteins have been reported in AD (Tham,
Nordberg et al. 1993). Reduced activity of IGF-1 may be due to increased levels of IGFBP.
Thus, bone loss may still be observed regardless of relatively high levels of total IGF-1.
Alternatively, IGF-1 resistance has been reported in AD (Salehi, Mashayekhi et al. 2008), which
may explain observed relationships between greater bone loss and relatively high levels of IGF-
1.
The results of our study should be interpreted with caution due to exploratory nature of
the study. Our study was based on synthesis of animal literature and statistical modeling.
Statistically modeled hypothetical causation may not be necessarily correct in a biological model
and is most likely an oversimplification. Additionally, we did not measure levels of free IGF-1 in
serum and levels of leptin or IGF-1 in the CSF and our conclusions were based on peripheral
levels of leptin and IGF-1. Our measures were taken once in the morning and did not assess
differences in fluctuations of these hormones. Much variance in bone loss remained unexplained
by potential involvement of central regulatory mechanisms within our model, additional or
alternative mechanisms may contribute to these relationships in the very early stages. We did not
account for other potential mechanism such as change in sex hormones, actual activity of SNS,
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detailed nutritional status and effects of other local and systemic mediators of bone remodeling.
Another limitation of our study is relatively small sample size that does not allow us to explore
the effects of gender on observed relationships.
This study extends previous findings by suggesting that bone loss secondary to AD may
be mediated by neurodegenerative changes (atrophy) in the hypothalamus. Additionally, these
changes may in turn initiate a cascade of events including increase in peripheral levels of leptin
and decline in IGF-1. However the model of independent neural and neurohumoral arms that
contribute to bone loss in individuals with AD is perhaps oversimplified. The co-dependent
relationships among brain, bone, fat and metabolism should be further investigated in normal and
pathological conditions in humans and animal models to gain a better understanding of these
interrelationships and to provide a basis for clinical applications.
Altogether, we are the first to explore the potential effects of hypothalamic atrophy on
bone and possible mechanisms of bone loss secondary to AD. We conclude that it is conceivable
that central regulatory mechanisms of bone mass may be disturbed by neurodegeneration leading
to bone loss in participants in very early stages of AD.
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Table 6. 1 Sample characteristics at baseline and change over two years
Data represent means ± SD unless otherwise stated; AD – Alzheimer’s disease; MMSE – Mini
Mental State Exam;
BMI – body mass index; *P 0.05; **P0.001; ***P0.0001, tP<0.10 – trend; ns P>0.10
Non-demented
(n=64)
Early AD
(n=58)
Non-demented
(n=63)
Early AD
(n=58) baseline D
Age, y 73.8 ± 6.8 75.4 ± 6.3 ns
Gender, F/M 34/30 33/25 ns
Vitamin D, ng/ml 27.5 ± 8.0 24.1 ± 8.7 - - * -
MMSE 29.4 ± 0.8 26.2 ± 3.1 0.3 ± 1.1 3.6 ± 5.4 *** ***
Growth
Hormone, ng/ml 0.90 ± 0.94 0.85 ± 1.14 - - ns -
Insulin-like
Growth Factor-1,
ng/ml 118.9 ± 49.7 116.9 ± 44.3 35.7 ± 33.5 30.3 ± 30.9 ns ns
Leptin, ng/ml 12.6 ± 10.0 14. 8 ± 11.4 - 0.2 ± 6.0 - 7.3 ± 11.8 ns ***
BMI, kg/m
2
26.2 ± 3.8 25.8 ± 3.8 0.4 ± 1.3 -0.8 ± 1.8 ns t
Body Fat, % 33.6 ± 8.8 34.0 ± 10.4 0.04 ± 2.3 - 1.1 ± 4.3 ns *
Waste/hip
Circumference 0.87 ± 0.10 0.87 ± 0.08 -0.2 ± 0.08 -0.3 ± 0.06 ns *
Total Bone
Density, g/cm
2
1.16 ± 0.11 1.12 ± 0.12 0.01 ± 0.03 0.02 ± 0.03 t *
Total Bone
Density, % - - -0.95 ± 2.7% -2.1 ± 3.1% - *
Baseline
Change over time (D, baseline
minus follow-up) p-value
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Table 6. 2 Univariate correlates of bone density at baseline
BMI Lean Mass Fat Mass 25OHD Leptin HGH IGF-1 HV
ND
BMD
0.26* 0.70*** 0.15 0.18 -0.25t -0.21 0.31* 0.01
AD
BMD
0.32* 0.64*** 0.08 0.12 -0.07 -0.05 0.13 0.25t
ND non-demented; BMD – total body bone mineral density; AD – Alzheimer’s disease; BMI –
body mass index (kg/m2); Fat and lean masses in kg; 25OHD- serum levels of vitamin D;
HGH – human growth hormone; IGF-1 – total serum insulin-like growth factor 1; HV –
hypothalamic volume in cm3; *P 0.05; **P0.001; ***P0.0001, tP<0.10 – trend.
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Table 6. 3 Univariate correlates of percent change in bone density from baseline
BMI Lean
Mass
Fat
Mass
Baseline
Vitamin
D
Leptin Baseline
HGH
IGF-1 HV
ND
BMD
-0.09 -0.12 -0.11 -0.10 -0.23 -0.18 0.007 -0.01
AD
BMD
-0.004 -0.08 -0.02 0.33* -0.08 -0.2 0.22 -0.29t
ND non-demented; BMD – total body bone mineral density; AD – Alzheimer’s disease; BMI –
body mass index (kg/m2); Fat and lean masses in kg; 25OHD- serum levels of vitamin D;
HGH – human growth hormone; IGF-1 – total serum insulin-like growth factor 1; HV –
hypothalamic volume in cm3; *P 0.05; tP<0.10 – trend;  - for all but BMD = absolute change
over two years.
Figure 6. 3 Final results of path analysis
Final hypothetical model of the relationship between hypothalamic atrophy and bone loss;
– bone mineral density; IGF-1
hypothetical causation; β coefficients displayed along the errors; regression coefficients indicate
proportion of total variance explained by a hypothetical cause.
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- insulin-like growth factor 1; the errors indicate the direction of
BMD
127
Chapter 7
Discussion and Conclusions
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7.1 Summary of findings
The body of presented work extends the literature on a relationship between bone loss
and AD. Overall, the presented work provides evidence that accelerated bone loss observed in
individuals in the early stages of AD may be partially due to disruption of central regulatory
mechanisms by neurodegeneration. This is the first work to demonstrate that hypothalamic
atrophy is related to bone loss and this relationship may be mediated by leptin-dependent
mechanisms in humans with early stages of AD. Potential mechanisms of this association and
possible explanations of why bone loss is observed in AD will be discussed. This work has
applications for clinical practice in AD and aging and provides a basis for future studies.
Chapter 2. Bone Density and Brain Atrophy in Early Alzheimer Disease
The purpose of work in Chapter 2 was to compare bone health in the earliest clinical
stages of AD with non-demented aging and to determine whether BMD is associated with
cognitive performance and brain atrophy, which is used as a marker of neurodegeneration. We
hypothesized that bone density would be lower in early AD and that reduced BMD would be
associated with brain atrophy and cognitive decline. In this cross-sectional study, we found that
BMD is reduced in men and women in the earliest clinical stages of AD and associated with
brain atrophy and memory decline, suggesting that central mechanisms may contribute to bone
loss in early Alzheimer’s disease.
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Chapter 3. Reduced Limbic and Hypothalamic Volumes Correlate With Bone Density in Early
Alzheimer's Disease.
The aim of the cross-sectional study in Chapter 3 was to extend previous findings of the
association between BMD and neuroimaging markers of neurodegeneration by assessing both
global and regional measures of brain volume in early AD and non-demented aging, with a
specific focus on the hypothalamus. We demonstrated that in early AD, low BMD was
associated with low volume of gray matter in brain structures predominantly affected by AD
early in the disease, including the hypothalamus, cingulate, and parahippocampal gyri and in the
left superior temporal gyrus and left inferior parietal cortex. No relationship between BMD and
regional gray matter volume was found in non-demented controls. These results suggest that
central mechanisms of bone remodeling may be disrupted by neurodegeneration.
Chapter 4. Cross-sectional estimation of the hypothalamic volume by atlas-based VBM
compared to manual tracing in application to Alzheimer’s disease.
There is very limited guidance in the literature regarding neuroimaging studies of the
hypothalamic anatomy and useful methods to do so. VBM, is used for the global assessment of
the entire brain, and also allows measuring volumes of different brain regions including the
hypothalamus. In the work presented in Chapter 4, we tested and compared the performance of
VBM methods with the “gold standard” manual volumetry of the hypothalamus. The atlas-based
VBM volumetry showed promise as a useful tool for regional volumetry of the hypothalamus
and has advantages over manual tracing as it is currently used. The results of this study provided
guidance for method selection in our future studies.
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Chapter 5. Different predictors suggest different mechanisms of bone loss in AD and aging.
In the work presented in Chapter 5, we tested the hypothesis that AD may influence bone
density in cortical skeletal sites directly through pathological changes in the hypothalamus, the
major central regulatory structure of bone remodeling.. We previously reported lower BMD in
the early AD group and suggested that brain atrophy, specifically of the hypothalamus, was
associated with lower BMD in AD in a cross-sectional study. Considering often-seen lack of
associations between cross-sectional and longitudinal studies, the purposes of the study presented
in Chapter 5 were: (i) to extend previous findings of a direct association between hypothalamic
atrophy and bone density and (ii) to explore predictors of bone loss in AD in a longitudinal
study. We found that bone loss was accelerated in AD compared with non-demented controls for
the total body and legs. For AD participants, bone loss was associated with baseline levels of the
vitamin D and hypothalamic atrophy. For non-demented participants, bone loss was associated
with age, female gender and decline in physical activity. Different predictors of bone loss in AD
suggest that mechanisms of bone loss may differ in cognitively-normal aging and AD and that
neurodegeneration may contribute to bone loss in early AD.
Chapter 6. Role of Central Hypothalamic Mechanisms in Bone Loss in Alzheimer’s Disease:
Testing a Path Model
The purpose of the work presented in Chapter 6 was to extend previous observations by
assessing the roles of leptin and GH-IGF-1 in mediating a relationship between hypothalamic
structural changes and bone loss in AD. Using a hypothetical model with statistical structural
equation or path modeling, we demonstrated that hypothalamic atrophy had a direct effect on
bone loss. IFG-1 and leptin were not independently associated with bon loss although
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hypothalamic atrophy was associated with observed increases in leptin over two years in the AD
group. Additionally, increased leptin over two years was associated with declines in IGF-1. The
results of our study suggest that it is conceivable that central regulatory mechanisms of bone
mass may be disturbed by neurodegeneration in participants in very early stages of AD. Further
studies are needed to explore the role of brain atrophy in bone loss.
7.2 Overview of Possible Mechanisms of Bone Loss in AD
The association between bone loss and AD is well-documented. Nevertheless, bone
health in AD remains understudied and the mechanisms underlying the association between bone
loss and AD are not well understood. Multiple factors have been postulated to explain the
association of bone loss with cognitive decline and AD. Despite increasing evidence of a key
role that the hypothalamus plays in the regulation of bone mass (Ducy, Amling et al. 2000), the
hypothalamic atrophy due to AD has never been previously considered among potential
mechanisms. The direction of bone-AD relationship is unclear. Two scenarios are possible: (i)
common pathological mechanisms drive plaque and tangle formation, cognitive decline,
metabolic, hormonal and body changes in AD and (ii) loss of essential neurons due to AD results
in imbalance of the centrally regulated functions including energy metabolism and bone loss.
Given that AD is associated with extensive hypothalamic structural damage and hypothalamic
dysfunction; it is plausible that hypothalamic damage could result in clinically evident bone loss.
However, gaps remain in our knowledge about mechanisms of bone regulation and central
control of bone metabolism. The results of our study provide evidence that suggests it is
plausible that atrophy of the hypothalamus may lead to bone loss in AD and possibly to other
clinical symptoms of hypothalamic dysfunction.
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7.3 Summary of Finding in Relation to Theories of Brain-Bone Connection
We humans consider ourselves superior to any other species in the world. However, we
are still subject to the basic principle of biology. No life without energy. This is as important in
humans as in any other species. Just like most living organisms, we obtain our energy from
glucose.
Here we will introduce the current state of knowledge and theories on central regulatory
mechanisms of bone and energy metabolism and discuss several potential mechanisms of bone
loss. The first part is mostly concerned with how the brain regulates bone. The second part will
discuss some theories on why the brain regulates bone. As we discuss different aspects of this
study, the current state of knowledge, and theories in the field, we will try to make sense of the
question: Why do we highlight the importance of energy and glucose?
As discussed throughout the body of this work, several lines of evidence in animals and
humans strongly suggest that leptin, a fat-derived hormone, plays an important role on bone
metabolism (Ducy, Amling et al. 2000; Elefteriou, Takeda et al. 2004). A key role of leptin is in
regulating feeding and energy metabolism through regulating appetite and energy expenditure
via hypothalamic mechanisms in arcuate (ARC) nucleus have been discovered long before its
effects on bone (Zhang, Proenca et al. 1994; Farooqi and O'Rahilly 2009). Initially, animal
studies suggested that leptin acts on the leptinergic/peptidergic neurons in VMH that lead to
activation of SNS, β-2-adrenoreceptors on the osteoblasts and decreased proliferation, thus,
decreased bone formation. This pathway was described as neural arm of hypothalamic control of
bone remodeling and was believed to be independent of feeding mechanisms and hypothalamo-
pituitary hormonal mechanisms (neurohumoral arm) (Takeda, Elefteriou et al. 2002). More
recent studies suggested that instead of acting directly on hypothalamic neurons leptin signals to
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its receptors expressed on serotonergic neurons in the brainstem, thus utilizing serotonin as
secondary messenger to exert its own effect on VMH and ARC hypothalamic neurons (Yadav,
Oury et al. 2009). This actions cause decrease in serotonin production and results in less
inhibition of neurons in VMH and increased sympathetic activity. Serotonin is also found to
stimulate IGF-1 release (Schaeffer and Sirotkin 1997). It may be speculated then that decrease in
serotonin may cause reduction in IGF-1 and subsequent bone loss via complimentary
mechanisms. Reported often inverse relationship between leptin and IGF-1 may be also mediated
by this mechanism. Important though, fat derived leptin also negatively regulates insulin
secretion by a direct effect on pancreatic cells (Covey, Wideman et al. 2006; Tuduri, Marroqui et
al. 2009). Bone-derived hormone osteocalcin in turn regulates energy metabolism by positive
effects on pancreatic β -cell proliferation, insulin secretion and sensitivity (Lee, Sowa et al.
2007). Leptin, through discussed earlier mechanisms, stimulates sympathetic tone which
decreases octeocalcin bioactivity (Hinoi, Gao et al. 2008), thus regulating insulin secretion
though yet another mediators – bone (Hinoi, Gao et al. 2009). It may be speculated therefore that
the primary purpose of leptin-dependent central control of bone metabolism is to again regulate
energy metabolism. Why would there be such an obvious redundancy in the brain regulation of
energy metabolism?
No life without energy? Or should we say – no life without energy in the brain? In 2004
Achim Peters and the group proposed “The Selfish Brain” theory (Peters, Schweiger et al. 2004;
Peters 2011). In short, “The Selfish Brain” theory states that the ability of the individual to
maintain its homeostatic energy balance greatly depends on the ability of the brain to
competently demand energy from the body. An average size human needs 200g of glucose every
day. Earlier theories wrongly hypothesized that this energy is equally distributed between the
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brain and the body. The brain however consumes 2/3 of the daily glucose supply (Reinmuth,
Kogure et al. 1968). In stress conditions, for example, the brain demands are even higher. “The
Selfish Brain” theory proposes that the energy is distributed within the organism on a
competitive basis between the brain and the body. Most importantly, the brain prioritizes the
regulation of its own energy content and sufficiency, demanding energy from the body and its
deposits when needed. Under conditions of brain energy deprivation, existing central
hypothalamic mechanisms of energy metabolism regulation are able to suppress insulin
production and guarantee sufficient glucose supply for the brain (Mattson 2002).
In application to Alzheimer’s disease, this theory ties together with the data from physical
anthropology that demonstrated that AD shares close similarities with syndromes of deprivation
or starvation such as decrease in metabolic rate, reduction of anabolic hormone levels, activation
of hypothalamo-pituitary-adrenal axis, and insulin resistance (Heininger 2000; Reser 2009).
These syndromes represent metabolic reduction program or simply thrifty ways to minimize
energy expenditure and support supply of energy to the brain – the most vital organ in the human
body.
The results of our studies do not directly answer either how or why questions. They are in
line with the enormous body of evidence that bone loss in AD may be driven by hypothalamus -
dependent mechanisms. Moreover, our results allude to the possibility that bone loss via
metabolic mechanisms in AD may be either a “side effect”, or even one of the mechanisms of
allocation of energy recourses to meet damaged brain’s demands for energy.
This author concludes that future studies on body changes, including bone loss in AD,
should not only explore how it happens but also the why it happens aspects of the problem.
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7.4 Clinical Implications
Clinicians need to pay attention to bone issues in women and men at risk for AD and
those who have already been diagnosed. In the absence of a cure for AD, the goal for the
clinicians, patients and caregivers is to prolong independence and delay institutionalization in
patients with AD. While cognitive deterioration is the major concern, co-morbidities definitely
contribute to the burden of caring for demented older people. Hip fracture is one of the common
devastating events in the elderly that greatly impacts independence of patients and puts
additional stress on caregivers. As the western societies progressively age, vitamin D deficiency
reaches epidemic levels and exercise becomes optional, we will face a dramatic increase in a
number of older people with dementia and hip fracture.
This work contributes to understanding the mechanisms that relate AD and bone loss. If
years from now we that are we can target modifiable common mechanisms and risk factors by
specific interventions, we would be able to influence development or reduce severity of both
conditions and promote healthy aging. If it turns out that one condition influences the occurrence
of the other, identifying mediating mechanism may provide strategies to decrease burden of co-
morbidities. While important discoveries are still in the future, results of our study once again
emphasize the importance of physical activity and vitamin D in bone health.
7.5. Limitations
Study Design and Sample Size
The observational nature of this work did not allow us to manipulate important predictor
variables to assess cause-effect relationship. However, observational data provides an important
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step in generating hypotheses and to justify and guide clinical trial development on bone loss in
AD. This study allowed us to begin to examine important variables that relate to bone density
and bone loss in AD. For example, a well-described protective effect of fat mass on bone was
not supported by the results of our study though the study is limited by a relatively small sample
size or short follow-up time that may influence our power to observe relationships. The study is
also limited in its ability to study gender differences. The floor-effect of some of the measures
(perhaps, physical activity or brain atrophy measures) may limit our ability to fully examine the
influence of covariates on BMD. We did not examine environmental (diet) and several peripheral
factors related to bone health including sex hormones or calcium, although we did take into
account participant use of such therapies. Given that our study participants are a convenient
sample composed primarily of Caucasians, it remains possible that our results may be influenced
by sampling bias and have limited generalyzability. Additionally, our AD sample was confined
to the earliest clinical stages of AD, with most of the demented subjects (80.3%) were in the very
mild (CDR 0.5) stage, comparable to mild cognitive impairment. Although this very early AD
group is one of the strengths of the study, it limits the range of dementia severity and may have
reduced our power to resolve a relationship between BMD and dementia severity and other
variables.
Bone Density Measures
In our work, the total body BMD loss values were smaller in respect to the least
significant change (0.9*2.77=2.6%) in all but women with AD. While, significant difference was
still observed in bone density and rates of bone loss between non-demented and AD groups, it
could take less time to see these differences if CV for total body reliability is lowered to widely
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reported 0.5% for the same densitometer version. It should be considered in designing future
studies and accounted for by either reducing the CV or increasing the length of the study.
Neuroimaging
Neuroimaging analytic choices for studying the hypothalamus are limited due to
challenges in subcortical segmentation (classification of brain regions). The VBM approach
allows for more accurate classification of brain tissues in presence of excess atrophy or abnormal
morphology. While use of this approach is increasing in popularity and has many advantages
over other methods, its applications in longitudinal studies have been only emerging. Several
issues with this approach have been brought to attention of researchers including well-recognized
sensitivity of VBM to intra- and inter-scanner variations, difference in scanning protocols and
contrast non-uniformity that may affect final volumetric results especially in a longitudinal
study. Results of our neuroimaging study should be interpreted with caution, although we
checked every original image for artifacts, movement, contrast issues as well as tissue maps after
being processed by VBM. Images that had artifacts which could not be corrected by remedy
strategies were excluded from the analysis. Additionally we validated the VBM method against
the “gold standard” manual tracing and concluded that manual tracing of the hypothalamus does
not have a superior performance for the purposes of our work.
Medications
Participants who reported taking bone affecting medications were not excluded from the
data analysis. Self-reported medication records were collected. Hormone-replacement therapy
medications (estrogen, testosterone and selective estrogen receptor modulators), thyroid hormone
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replacement, bisphosphonates, beta-blockers, vitamin D and calcium were considered as bone
affecting. While low bone density was perhaps the reason for taking most of these medications,
the number of participants receiving the medications was small and the proportion of these
individuals in both groups was equal. Additionally, these medications did not affect group
average rates of bone loss over two years.
Statistical Path Modeling
The path analyses cannot test real-world directionality in relationships. The directions of
arrows in a structural equation model are based on the researcher’s hypotheses of causality
within a system. The choice of variables and pathways limits the ability of the models to recreate
relationships in natural biological systems and oversimplifies the reality. Not surprisingly,
several models that represent the concept may fit the data equally well. This approach is useful in
understanding relationship patterns in complex systems. The ability of this approach to data
analysis to distinguish between direct and indirect paths, allows a better understanding of
complex concepts and identification of influential modifiers.
7.6 Future directions
The regulatory mechanisms of bone metabolism and bone loss are extremely complex.
Many factors involved in regulation of bone homeostasis are pleiotropic and have profound
multiple effects. The effects may include regulating each other or functioning beyond the bone
metabolism. The fascinating fact about hormonal systems is that they are also regulated by a
negative feedback loop. As discussed throughout this body of work, many factors have already
been identified in the central regulatory mechanisms on bone remodeling. The pathway expands
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with every new fact. It is apparent that we know only a small portion about central regulatory
mechanisms of bone remodeling and we know very little about the role of the hypothalamus in
bone regulation in humans. The results of this body of work suggest that the hypothalamic
mechanisms are involved in bone loss in individuals with AD. Based on observations by other
researchers and results of this work we propose several directions in future studies.
Observational studies on mechanisms of bone loss.
The hypothesis that neurodegeneration in AD may disrupt central regulatory mechanism
of bone remodeling was proposed and tested in human studies for the first time. Attention to this
possibility is emerging in different clinical conditions. For example, recent review on bone loss
in patients with spinal cord injuries suggested that disruption of the spinal cord tracts may also
lead to “neurogenic” bone loss (Qin, Bauman et al. 2010). Although, it seems logical that
processes regulated by CNS would be affected by neuronal death in critical brain structures, this
hypothesis is difficult to test in humans. Bone loss in AD is a significant clinical problem. As an
extension for this work, future studies should characterize other potential mediators of central
mechanisms of remodeling (e.g. serotonin or sympathetic nervous system output) in relation to
bone mass and bone loss in humans and whether these relations change in neurodegenerative
diseases, such as AD. Better characterizing a relationship between bone loss and peripheral total
and free IFG-1 may be important. IGF-1 is an anabolic factor that is responsive to physical
activity (Rojas Vega, Knicker et al. 2010), thus is potentially modifiable by treatment
interventions. Likewise, identifying other modifiable factors associated with bone loss may
inform future clinical trials and lead to new intervention.
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Hypothalamic atrophy and dysfunction
Mounting evidence supports that AD is associated with multiple signs of hypothalamic
dysfunction. Therefore, in the context of proposed hypothesis, the association between
hypothalamic structural damage and its functions should be explored. Future studies may assess
whether clinical observations of sleep, mood and appetite disturbances, abnormal sexual
behaviors, and impaired energy metabolism and thermoregulation in AD (Wu and Swaab 2007;
de Medeiros, Rosenberg et al. 2008; Di Iulio, Palmer et al. 2010) will be associated with
hypothalamic atrophy.
Clinical trials: Exercise for bone health
Although we did not find an association between habitual physical activity and bone loss
in AD we think that was due to extremely low levels of engagement in the strenuous physical
activities, the most beneficial for bone health. Perhaps, individuals with AD reduce these
challenging activities in the pre-clinical stages (Scarmeas, Luchsinger et al. 2009). This question
is important and should be investigated in the future studies.
Physical activity provides great benefits for general health. The data on effects of
exercise on bone health in older adults is contradictory. In older men and women, reports range
from clinical trial observations that several exercise interventions (including resistance training
or regular walking by itself) have no benefits for bone health, to others concluding that for these
interventions to be effective, they should be fast, intense and use heavy loads (see (Guadalupe-
Grau, Fuentes et al. 2009) for full review), suggesting a need for further studies to address this
inconsistency. While clinical trials for effects of exercise on cognitive function in AD are
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emerging, up to date no studies have looked at the effects of exercise intervention on bone health
in individuals with AD.
Therefore, future clinical trials should investigate the effects of physical activity as a
potential preventive or therapeutic strategy on bone health in AD. The activities that utilize high-
impact or odd-impact (e.g. jumps, tennis, soccer, golf and dance) are found to be the most
effective for bone health (Nikander, Kannus et al. 2009). These are also high risk activities for
adverse events, so they cannot be used as sports, but rather the main components should be
incorporated in safe interventions. Considering cognitive deficits, frailty and increased risk for
falls, in patients with AD, future studies should focus on designing and testing effective, easy to
comprehend, safe exercise interventions enjoyable for both genders.
Clinical trials: Vitamin D supplementation for bone health in AD
Vitamin D is one of the main factors related to bone health. Our results demonstrated that
prevalence of vitamin D deficiency is higher in AD. Low levels of vitamin D were also
associated with increased bone loss. Recent systematic review on vitamin D supplementation in
relation to bone health in older adults reported that numerous clinical trials provide fair evidence
that vitamin D supplementation increases levels of 25 OH D and improves bone health (Cranney,
Weiler et al. 2008). Similar systematic review in AD however identified only 3 clinical trials on
effects of combination of risedronate sodium (Actonel®, a bisphosphonate used to treat
osteoporosis) and vitamin D with several for risk of fractures in severely demented women
residing in nursing homes (Iwamoto, Sato et al. 2009). This suggests a clear need for more high –
quality trials of vitamin D supplementation in relation to bone health outcomes in women and
men with AD.
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Neuroimaging
Considering that applications of modern neuroimaging techniques in the longitudinal
studies are just emerging, it is important to test new and improved techniques in studying the
hypothalamus in order to identify the ones that are less affected by imaging artifacts, time
between brain scans and different scanners.
Based on our results, the current methods can also be improved by, first, creating a manual
hypothalamic mask using MRI brain images and validating results with autopsy-defined volume
and shape of the hypothalamus, similar to study design by Bobinski et al. (Bobinski, de Leon et
al. 2000). Next, utilizing the mask in automated approaches will allow fast and reliable
assessment of structural changes in AD and other condition associated with hypothalamic
dysfunction.
7.7 Summary of conclusions
The body of presented work extends the literature on a relationship between bone loss
and AD. Overall, the presented work provides initial evidence that accelerated bone loss
observed in individuals in the early stages of AD may be partially due to distortion of central
regulatory mechanisms by neurodegeneration. This is the first work to demonstrate that
hypothalamic atrophy is related to bone loss and this relationship may be mediated by leptin-
dependent mechanisms in humans in the early stages of AD. The findings of this work indicate a
need for future studies to determine a role of neurodegeneration in centrally regulated body
functions and mechanisms of physical decline, including bone loss in AD.
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